Clinical Research Protocol
Version  12/10/2018
A Pi[INVESTIGATOR_58738] (TSC) and Focal Cortical Dysplasia (FCD)
IND Sponsor: Orrin Devinsky,  MD 
Department of Neurology 
NYU Langone Medical  Center  
[ADDRESS_63899]
[LOCATION_001], NY [ZIP_CODE] 
Phone:
 [PHONE_1062]
Funding Sponsor: Departmental
[ADDRESS_63900], [LOCATION_001], NY [ZIP_CODE] 
[PHONE_1062]
Study
 Agent: Everolimus
Protocol Number: S14-[ZIP_CODE]
IND Number: 118831
Initial version: 8/12/2014[STUDY_ID_REMOVED]
CONFIDENTIAL
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_58828]:  09/20/18Page ii
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58829] ......................................................................................................................................1
1INTRODUCTION....................................................................................................................................... 3
1.1 B ACKGROUND ...................................................................................................................................... 3
1.2 I NVESTIGATIONAL AGENT  ................................................................. ERROR! BOOKMARK NOT  DEFINED.
1.3 PRECLINICAL  DATA ............................................................................................................................5
1.4 CLINICAL  DATA RELATED TO STUDY DRUG USE...................................................................................5
1.5 DOSE RATIONALE AND RISK/BENEFITS ................................................................................................[ADDRESS_63901] R ECRUITMENT AND SCREENING .........................................................................................13
4.4 EARLY WITHDRAWAL OF SUBJECTS ..................................................................................................14
4.4.1 When and How to Withdraw Subjects .................................................................................... 14
4.4.2 Data Collection and Follow-up for Withdrawn  Subjects .........................................................14
5 STUDY  DRUG......................................................................................................................................15
5.1 DESCRIPTION & PACKAGING ............................................................................................................. 15
5.2 TREATMENT  REGIMEN ...................................................................................................................... 16
5.3 STUDY DRUG  ADMINISTRATION .........................................................................................................17
5.3.1 Management of specific toxicities ..........................................................................................17
5.3.2 Dose Adjustments ..................................................................................................................22
5.3.2 Serum Drug Levels 22
5.4 METHOD FOR ASSIGNING  SUBJECTS TO TREATMENT GROUPS ............................................................22
5.5 PRIOR AND CONCOMITANT THERAPY ................................................................................................22
5.6 BLINDING OF STUDY DRUG ...............................................................................................................23
5.7 RECEIVING ,  STORAGE, DISPENSING AND  RETURN ..............................................................................23
5.7.1 Receipt of Drug Supplies .......................................................................................................23
5.7.2 Storage & Handling................................................................................................................23
5.7.3 Dispensing of Study Drug ......................................................................................................23
5.7.4 Return or Destruction of Study Drug ......................................................................................23
6 STUDY  PROCEDURES .......................................................................................................................23
6.1 VISIT  1............................................................................................................................................23
6.2 VISIT  2............................................................................................................................................24
6.3 VISIT  3 – DAY OF SURGERY ..............................................................................................................25
6.4 VISIT  4 (AND ALL DAYS WITH INVASIVE  ELECTRODES)..........................................................................26
6.5 VISIT  5A (IF A SECOND  SURGERY IS DONE AT THE END  OF INVASIVE  RECORDINGS) ................................26
6.6 VISIT  5B (POSTOPERATIVE DAY 2 AND  ALL DAYS  UNTIL DISCHARGE) .....................................................27
6.7 VISIT  6............................................................................................................................................27
7 STATISTICAL PLAN ............................................................................................................................27
7.1 SAMPLE S IZE DETERMINATION ..........................................................................................................27
Everolimus  ef fects on brain mTOR  and excitability
Version:  09/20/18Page ii
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58830]7.2 ADVERSE  EVENTS ...........................................................................................................................28
7.3 SERIOUS ADVERSE  E VENTS .............................................................................................................30
7.3.1 Definitions .................................................................................................................................30
7.3.2 Reporting ..................................................................................................................................30
7.3.3 Investigator reporting: Notifying the -NYULMC  IRB...............................................................31
7.3.4 Investigator reporting: Notifying a non-NYUMC  IRB..............................................................32
7.3.5 Sponsor reporting: Notifying the FDA ....................................................................................33
7.3.6 Sponsor reporting: Not ifying participating investigators 33
7.4 UNBLINDING  P ROCEDURES ...............................................................................................................33
7.5 STOPPI[INVESTIGATOR_1645]  R ULES ............................................................................................................................33
7.6 Source Documents 35 7.7 Case Report 
Forms………………………………………………………………………………………..[ADDRESS_63902] S TIPENDS OR PAYMENTS .................................................................................................40
11 PUBLICATION PLAN ........................................................................................................................40
12 REFERENCES .....................................................................................................................................40
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page [ADDRESS_63903] Barnabas 
NYU CEC
 [LOCATION_001] University Comprehensive Epi[INVESTIGATOR_58739] 1 Everolimus  ef fects on brain mTOR  and excitability
Version:09/20/18
CONFIDENTIAL
This material is the propert y of the NY U School of Medicine and Langone Medical Center.  Do not disclose or use except  as 
authorized in writing by [CONTACT_58832][INVESTIGATOR_58740] (TSC) and Focal 
Cortical Dysplasia (FCD)
Short Title Everolimus effects on brain mTOR and excitability
Protocol Number Pending
Phase 2
MethodologyThis is a  multi  center, open-label exploratory Phase II clinical trial of patients 
with treatment resistant epi[INVESTIGATOR_002] (TRE), ages 2 to 50 years old, with TSC or 
FCD who are scheduled for epi[INVESTIGATOR_58741].
Study Duration 18 months of active recruitment
Study Center(s) NYU Langone Medical Center;
ObjectivesPrimary objectives: A pi[INVESTIGATOR_58742]:
1) feasibility and safety of recruiting patients into a prospective study for 
patients with TSC and FCD treated for 7-21 days before epi[INVESTIGATOR_58743] 2) test the hypothesis that everolimus  therapy in TSC and FCD patients 
with TRE will reduce mTOR signaling (reduced S6 phosphorylation) as 
compared to concurrent controls with TSC and FCD who did not receive 
Everolimus.
Secondary Objectives:  to obtain preliminary data on the effect of everolimus 
therapy in TSC and FCD patients with TRE on mTOR signaling and cortical 
hyperexcitability by [CONTACT_58833] 1) systemic mTOR signaling suppression 
(VEGF-D) pre- and post-treatment, 2) relation of S6 phosphorylation to specific 
genetic abnormalities, and 3) blood everolimus levels; and using historical  
controls to assess 4) markers of cortical hyperexcitability (glutamate and  
GABA receptors, levels of neuroinflammation (TNF-α), axonal abnormalities, 
myelination defects), and 5) electrocorticographic (ECoG) recordings
Number of Subjects21 total subjects study wide; 9 treated subjects (NYU CEC) and 12 controls  
(@ NYU CEC;)
This has been a very challenging study to recruit for and therefore our total  
number of enrolled patients is fewer than expected.  This has to do with 
multiple factors, including a smaller number of eligible candidates, a smaller 
percentage of parents who have considered to participate, and the challenge 
imposed by [CONTACT_58834]. Given this distance, enrollment of subjects 3-[ADDRESS_63904] shortened the length of the 
treatment phase.
Diagnosis and Main  
Inclusion Criteria1.Female and male patients, age 2 year to 50 years
2.Diagnosis: treatment  resistant epi[INVESTIGATOR_002] ( > 2 failed  anti-epi[INVESTIGATOR_32551] [AED]  
treatment regimens) and either:
●Tuberous Sclerosis Complex (TSC)
●Focal Cortical Dysplasia (FCD) on MRI
Number of Subjects  
in comparison 
control group12 subjects
E v er oli m u s  eff e ct s  on br ai n  m T O R  a nd e x cit a bilit y
V er si o n :  0 9/ 2 0/ [ADDRESS_63905] u d y I ND s p o n s orDi a g n o si s a n d  M ai n  
I n cl u si o n Crit eri a1 .F e m al e a n d m al e p ati e nt s, a g e 2 y e ar t o 5 0  y e ar s
2 .Di a g n o si s:  tr e at m e nt r e si st a nt e pil e p s y  ( > [ADDRESS_63906] u g  
[ A E D] tr e at m e nt r e gi m e n s) u n d er g oi n g r o uti n e s ur g er y
●T u b er o u s S cl er o si s C o m pl e x  ( T S C)
●F o c al C orti c al D y s pl a si a ( F C D) o n  M RI
St u d y Pr o d u ct,  D o s e,  
R o ut e,  R e gi m e nE v er oli m u s:
●P ati e nt s N O T t a ki n g EI A E D s : T h e st arti n g d o s e of e v er oli m u s f or 
tr e at m e nt p ati e nt s  will  b e  4. 5  m g/ m2  o n c e  d ail y;  a dj u st  t o att ai n  tr o u g h 
c o n c e ntr ati o n s of 5- 1 5 n g/ ml. T h e d o s e will b e a dj u st e d f or c ert ai n  c o- 
m e di c ati o n s ( s e e  b el o w).
●P ati e nt s T A KI N G C Y P 3 A 4 a n d/ or P- gl y c o pr ot ei n ( P g P)  I n hi bit or s 
P ati e nt s will  b e e x cl u d e d if u si n g str o n g C Y P [ADDRESS_63907] u g wit h m o d er at e  C Y P 3 A 4  
a n d/ or P g P i n hi bit or s, t h e e v er oli m u s d o s e will b e r e d u c e d  b y  
a p pr o xi m at el y 5 0 % t o m ai nt ai n tr o u g h c o n c e ntr ati o n s of 5 t o 1 0  n g/ m L.  
N o m o d er at e or str o n g C Y P 3 A 4 a n d/ or P g P i n hi bit or will b e a d d e d  or  
di s c o nti n u e d d uri n g t h e st u d y  p eri o d.
●P ati e nt s T A KI N G o n e c o n c o mit a nt str o n g C Y P 3 A 4 i n d u c er f or  s ei z ur e 
c o ntr ol ( e. g., p h e n yt oi n, c ar b a m a z e pi n e, p h e n o b ar bit al) will b e  all o w e d  
i n t h e st u d y. P ati e nt s t a ki n g m or e t h a n o n e str o n g C Y P 3 A 4 i n d u c er  
will b e e x cl u d e d. F or p ati e nt s r e q uiri n g a c o n c o mit a nt str o n g  C Y P 3 A 4  
i n d u c er ( a n E n z y m e-I n d u ci n g A nti e pil e pti c Dr u g ( EI A E D), w e will  
d o u bl e  t h e e v er oli m u s  d o s e  fr o m t h at pr e s cri b e d  f or p ati e nt s  n ot  t a ki n g 
EI A E D s
D ur ati o n  of  
a d mi ni str ati o n7 t o  [ADDRESS_63908] s,  t h er e ar e  
t w o c a s e s of w o u n d h e ali n g pr o bl e m s or t hr e e c a s e s of s eri o u s i nf e cti o n, 
i n cl u di n g w o u n d sit e i nf e cti o n. I n t h e c a s e of a w o u n d sit e i nf e cti o n, a n y  
pr o bl e m s  wit h  w o u n d  h e ali n g  will  b e  c o n si d er e d  s e c o n d ar y  t o t h e i nf e cti o n a n d  
N O T a s a pri m ar y w o u n d h e ali n g pr o bl e m. T h e s e e sti m at e s ar e b a s e d  o n  
n e ur o s ur gi c al e x p eri e n c e a n d r e p ort s wit h t h e fr e q u e n c y of w o u n d  h e ali n g  
pr o bl e m s of < 2 % a n d i nf e cti o n fr o m 1. 6 t o 8. 6 % i n p u bli s h e d s eri e s, wit h  a 
m e a n i nf e cti o n r at e of  5. 3 %.
F or  t h e a n al y si s  of  S [ADDRESS_63909] a diff er e n c e of │ 1. 4 │-  │ 1. 5  │ st a n d ar d  d e vi ati o n s b et w e e n t h e 
c o m p ari s o n c o ntr ol s a n d t h e tr e at e d gr o u p wit h [ADDRESS_63910] s wit h  al p h a
= 0. 0 5 a n d  p o w er of 8 0 %. Pr eli mi n ar y d at a u si n g q u a ntit ati v e W e st er n bl ot s  
o bt ai n e d fr o m [ADDRESS_63911] e d t u b er s d e m o n str at e d p h o s p h o- S 6/ S 6 r ati o s  of  
2 5 7  4 2 %  of  c o ntr ol.  Wit h  [ADDRESS_63912]  a  6 4  –  6 5 %  diff er e n c e  i n p h o s p h or- S 6/ S 6  l e v el s b et w e e n  tr e at e d a n d  
u ntr e at e d  gr o u p s,  w hi c h  i s li k el y a  bi ol o gi c all y  m e a ni n gf ul  diff er e n c e.
Everolimus  ef fects on brain mTOR  and excitability
Version:  09/20/18Page 3
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58830]1 Introduction
This document  is a  protocol for a human  research  study.  This study is to be conducted in accordance with 
US government research regulations, and applicable international standards of Good Clinical Practice, 
and institutional research policies and procedures.
1.1 Background
Early onset  and treatment-resistant  epi[INVESTIGATOR_002] (TRE)  commonly complicates  Tuberous Sclerosis Complex 
(TSC) and focal cortical dysplasia (FCD) and can contribute to or cause severe cognitive and behavioral 
impairments in these patients. In the case of TSC, the genetic loss of TSC1/TSC2 inhibition results in 
upregulation of the mTOR signaling pathway causing multiple structural  and functional  alterations in the 
brain that contribute to epi[INVESTIGATOR_002], although the specific alterations that cause epi[INVESTIGATOR_58744]. 
Many patients with TSC and FCD who have TRE benefit from epi[INVESTIGATOR_58745] 
a single epi[INVESTIGATOR_58746]. However, a multicenter study of 70 patients undergoing epi[INVESTIGATOR_58747] 53% became seizure-free after surgery [1]. Thus,  nearly half of patients  experience  
seizures after surgery while many others do not qualify for epi[INVESTIGATOR_58748]. TRE has a high morbidity, especially for TSC patients,  in which autistic 
spectrum disorder  and intellectual  disability are associated with frequent seizures  and early life onset  
epi[INVESTIGATOR_002] [2] [3]. Further, the risk of sudden unexpected death in epi[INVESTIGATOR_58749]-clonic seizures during  the past year,  early-onset epi[INVESTIGATOR_002], long-duration of epi[INVESTIGATOR_002], 
and symptomatic epi[INVESTIGATOR_002]. In some studies, after adolescence, sudden unexpected death in epi[INVESTIGATOR_58750] 10% per decade  for individuals with multiple risk factors [4], which are present in many TRE 
patients with TSC or FCD.
mTOR inhibition in animal models of TSC has anti-epi[INVESTIGATOR_58751]-epi[INVESTIGATOR_58752], and 
preliminary data suggest  that mTOR inhibitors can reduce seizure frequency in some TSC patients.  The 
rationale for studying everolimus in TSC is straightforward given the known effect of TSC1 and TSC2  
mutations on mTOR  activity,  the effect of mTOR inhibition in animal  models of TSC to reduce both the 
development (epi[INVESTIGATOR_58753]) and occurrence (antiseizure) of seizures [5] [6, 7], and preliminary human 
data suggesting that everolimus  can reduce seizures  in TSC patients  [8]. For FCD, studies from human 
brain tissue  reveal  that balloon cells exhibit robust phosphorylation of S6 protein in a pattern  similar  to 
giant cells in cortical  tubers from patients with TSC [9-11]. Furthermore,  brain  tissue  from FCD and TSC 
cases has similar cellular (e.g., balloon cells) and architectural (e.g., dyslamination) changes, further 
supporting shared pathogenetic mechanisms [12]. Additionally, FCD tissue  expresses similar patterns of 
dysregulated excitatory  and inhibitory neurotransmitter  receptors as those  observed in TSC [13, 14].
Together, these findings  suggest that, as with TSC, in FCD, there is upregulation of mTOR  activity in the 
brain and this may directly contribute to seizure activity. Given these brain molecular and structural 
parallels between TSC and FCD, and the significant morbidity (e.g., depression; psychosis; memory, 
language and other cognitive impairments) and mortality (e.g., sudden unexpected death in epi[INVESTIGATOR_002],  
drowning, status  epi[INVESTIGATOR_7397], suicide) associated with TRE, this pi[INVESTIGATOR_58754]. Further, for the FCD group  or individual patients, 
if this study finds evidence that an mTOR  inhibitor can down-regulate excess mTOR activity and restore 
excitatory/inhibitory neurotransmission  and reduce neuronal hyperexcitability, a subsequent  trial of an 
mTOR inhibitor would  have potential  therapeutic benefit.
No randomized clinical  trial  has demonstrated efficacy  of mTOR inhibitors in seizure  suppression,  and the 
potential mechanisms of action have not been investigated. The goal of this study is to obtain data to help 
plan an exploratory Phase  II clinical trial to assess the efficacy of everolimus therapy to improve the 
molecular and electrophysiological abnormalities in the brains of TSC and FCD patients with  TRE.  
Patients enrolled in this study will receive everolimus  for a minimum of [ADDRESS_63913] patients everolimus for six months or longer in clinical trials of patients with TSC with 
subependymal giant cell astrocytomas (SEGAs) of the brain [8]. The effectiveness  of everolimus in this 
setting was based on reduced SEGA volume. These authors noted that 16 patients for whom 24-hour
Everolimus  ef fects on brain mTOR  and excitability
Version:  09/20/18Page 4
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58835], seizure frequency for the 6-month study period 
decreased in 9, did not change  in 6, and increased in 1 (p=0.02). However, a clinical benefit  for epi[INVESTIGATOR_58755].
Our rationale for a short-term (7-21 days) treatment is based on prior work in animal models showing 
cellular changes in mTOR signaling (down-regulation) after only 24 hours of treatment [5]. This effect of 
mTOR inhibition on mTOR signaling and epi[INVESTIGATOR_58756], however, was only demonstrated 
in patients with glioblastoma multiforme, a tumor associated with disruptions of the blood-brain barrier  
(see below)  [15].
Despi[INVESTIGATOR_58757]  “proof  of  concept” data for everolimus treatment in patients  with TRE who have 
TSC or FCD, clinical trials of TSC patients  have nevertheless been conducted. To date, no adequately 
powered, prospective studies have addressed the efficacy of everolimus  in patients with TSC who have 
TRE. One small study is ongoing to assess the efficacy and safety of everolimus in TSC patients  with  
TRE and we will monitor the results of this study as they become available. No studies have examined  
the effects of everolimus in TRE in patients with FCD. We believe that our study of brain tissue obtained  
at the time of epi[INVESTIGATOR_58758], as well as ECoG data, will provide the first in 
vivo evidence of a biologic  effect  of everolimus in human epi[INVESTIGATOR_58759]. We have a unique 
opportunity to demonstrate this in human  TSC and FCD patients undergoing epi[INVESTIGATOR_58760]. Defining the molecular  and electrophysiological 
changes of mTOR inhibition in human brain tissue may provide critical insights into the efficacy, 
tolerability, and limitations of this therapy.  A better understanding  of the effects of mTOR inhibition on 
mTOR signaling, neurotransmission, and epi[INVESTIGATOR_58761]-targeted therapi[INVESTIGATOR_58762],  and for designing and a clinical trial. 
This study is a logical next step based for both pre-clinical studies and preliminary clinical data on the 
effect of everolimus  on seizures in TSC patients. Our study  may help to explain why some patients treated 
with mTOR  inhibitors fail treatment, as well as help elucidate the effect  of these  agents on epi[INVESTIGATOR_58763].  Therefore,  data  obtained  from  the  proposed  studies     may                  
help guide future treatment with mTOR inhibitors.
The goals of  our pi[INVESTIGATOR_58764] a prospective,  multi-center Phase II 
study of everolimus for TRE in TSC and FCD. Our pi[INVESTIGATOR_58765], assess safety, identify challenges to study methodology, dosing of everolimus 
(e.g., relation of dose (mg/m2/day) to serum level, relation of serum and potentially  brain  levels if a reliable 
assay can be identified before this subsequent study) and cellular physiological effects of everolimus  
(e.g., inhibition of neuronal mTOR activity, changes in excitatory/inhibitory neurotransmission, reduction   
of cortical excitability), and the relation of changes  in mTOR activity  to different  genetic  abnormalities in 
brain tissue. The study may also provide  initial  data on the efficacy of everolimus  in reducing epi[INVESTIGATOR_58766] (ECoG).  The use of biomarkers – molecular signaling, cellular  
physiology, and cortical excitability – will provide sensitive indicators of the effects of everolimus on 
seizure foci. The data we acquire may also help to inform  the use of everolimus to treat SEGAs  and 
potential uses in cognitive  and psychiatric disorders that complicate TSC and FCD.
1.2 Overview of Everolimus
Everolimus
 is a  derivative  of rapamycin which acts as a signal transduction inhibitor (Table 1, Figure 1). 
Everolimus selectively inhibits mTOR (mammalian target of rapamycin), specifically targeting the mTOR- 
raptor signal transduction complex. mTOR  is a key serine-threonine kinase in the PI3K/AKT  signaling 
cascade, which is known to be dysregulated in a wide spectrum  of human cancers [37].
Table 1 Everolimus - Drug substance
Everolimus  ef fects on brain mTOR  and excitability
Version:  09/20/18Page 5
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58836]
H3C
O CH3
CH3
O O OH
N H3C
OOH C3O
O O
OH
H3C CH3
O O H3CChemical name (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-
dihydroxy-12-{(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1- 
methylethyl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4- 
aza-tricyclo[[IP_ADDRESS],9]hexatriaconta-16,24,  26,28-tetraene-2,3,10,14,20-
 
pentaone
International non- 
proprietary nameEverolimus
Figure 1 Chemical structure of  Everolimus
HO
CH3 CH3
Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), is FDA-approved as an 
antineoplastic agent. The molecular formula is C53H83NO14 and the molecular weight is 958.2
mTOR is a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is  
dysregulated in several human cancers. Everolimus  binds  to an intracellular protein, FKBP-12, resulting 
in an inhibitory complex formation with mTOR Complex 1 (mTORC1) and thus inhibition of mTOR  kinase 
activity. Everolimus  reduces the activity of S6 ribosomal  protein  kinase (S6K1) and eukaryotic  elongation 
factor 4E-binding protein (4E-BP1), downstream effectors  of mTORC1, involved  in protein synthesis. In 
addition, everolimus inhibits the expression of hypoxia-inducible factor (HIF-1) and reduces  the 
expression of vascular endothelial growth factor (VEGF).  Inhibition of mTORC1  by [CONTACT_58837], angiogenesis, and glucose  uptake  in in vitro and/or in vivo studies.
Two regulators of mTORC1 signaling are the oncogene suppressors hamartin (TSC1) and tuberin  
(TSC2), which together form a complex to inhibit mTORC1. Loss or inactivation of either TSC1 or 
TSC2 leads  to activation of downstream signaling. In Tuberous Sclerosis Complex (TSC), a genetic 
disorder, inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma  formation 
throughout the body.
1.[ADDRESS_63914] never been documented. The optimal  data for analyzing this risk 
would be the experience treating TSC or FCD patients receiving everolimus therapy who required 
neurosurgical intervention while on the medication. However, this clinical experience has not been
Everolimus  ef fects on brain mTOR  and excitability
Version:  09/20/18Page 6
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58838]. Further,  limited  information is  available regarding brain tumor patients  receiving everolimus who 
undergo neurosurgery. Two studies in patients with glioblastomas are cited below. The large datasets 
available are with everolimus use in other surgical settings, typi[INVESTIGATOR_58767] (e.g., kidney,  heart,  pancreas). However, the transplant patients are often chronically ill 
and immunosuppressed from chronic illness and other immunosuppressive agents as part of their 
treatment protocol.
mTOR inhibition with  rapamycin: Everolimus  in glioblastoma multiforme
Two trials of  mTOR inhibitors in the short term (~1 week) treatment of glioblastomas before brain  surgery 
failed to identify any evidence  of impaired  wound healing,  increased peri-operative  infections,  or bleeding  
[15,16]. Intratumoral rapamycin concentrations sufficient to inhibit mTOR in vitro occurred in all 15 
patients, but the degree of mTOR inhibition in tumor cells, as measured by [CONTACT_58839]  S6 protein 
phosphorylation, varied substantially [15]. Thus, although  the dose of rapamycin ranged from 2 to 10 mg 
per day (5-fold range), the tumor levels of rapamycin ranged from 0.3 to 36.3 nM (>100-fold range).
Further, rapamycin treatment  led to Akt activation in seven patients, presumably due to loss of negative  
feedback, and this activation correlated with shorter  time-to-progression during post-surgical maintenance 
rapamycin therapy (p < 0.05) [15]. In this trial, there were no grade 3 or 4 toxicities during the  
preoperative treatment or perioperatively. After recovery from surgery and resumption of therapy,  3 
patients developed grade 3 toxicities that were potentially related to therapy: hypokalemia,  
hypercholesterolemia, and cytopenias. All were managed with supportive care and none led to 
discontinuation.
In a trial  of everolimus for glioblastoma multiforme one week before surgery, 11 patients  were randomized 
to treatment with 5 mg daily (n=5) or 10 mg daily (n=10) [17]. None of these [ADDRESS_63915]- 
operatively, none developed infections. Notably, 63% of these patients were treated with dexamethasone  
and could have been immunocompromised as a result. Although dexamethasone may be used peri- 
operatively by [CONTACT_58840][INVESTIGATOR_58741], the dexamethasone therapy is 
associated only with the perioperative period whereas  patients  with glioblastoma multiforme  are often on 
dexamethasone chronically,  both before and after brain surgery. The glioblastoma patients are almost  
always on AEDs perioperatively and often  chronically, and many took other drugs (e.g., warfarin) that 
could complicate their perioperative course.
CCI-779, an mTOR inhibitor, was used to treat 43 patients with recurrent gilioblastomas.[17] Unlike the 
prior studies, the drug was administered as an ongoing therapy. In this study, the drug was well tolerated 
by [CONTACT_58841], anemia, stomatitis, and elevated lipi[INVESTIGATOR_58768].
There was no  reported increase in infections or wound healing problems.
Everolimus: effect on wound complications in organ transplantation
Several studies reviewed the surgical wound complications in patients receiving everolimus for organ  
transplantation, examining  large, randomized,  multicenter  clinical trials. Some studies found an increased 
risk of wound complications in the everolimus-treated groups. Multivariate analyses reveal  that this risk is 
higher in the presence of other well-known risk factors  for surgical wound healing, most notably increased  
body mass index (BMI).  This was most  robust for patients undergoing heart transplantation, but a similar 
effect was found after renal and pancreas transplantation.
A systematic reviewed of 37 randomized control trials in solid organ transplants comparjng mTOR 
inhibitors with other therapi[INVESTIGATOR_58769]/or lymphocele 
formation.[18] The pooled analyses showed a higher incidence of wound complications (OR 1.77, CI 
1.31–2.37) and lymphoceles (OR 2.07, CI 1.62–2.65) for kidney transplant  recipi[INVESTIGATOR_58770]. There was also a higher  incidence of wound  complications  (OR 3.00, 
CI 1.61–5.59) and lymphoceles (OR 2.13, CI 1.57–2.90) for kidney transplant recipi[INVESTIGATOR_58771]. A retrospective study of 513 kidney transplant patients  found  
wound healing problems in 19% with elevated BMI as the greatest risk factor  [25]. A retrospective
Everolimus  ef fects on brain mTOR  and excitability
Version:  09/20/18Page 7
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58842] 97  liver transplant patients found no increase in poor wound healing  events  associated  with 
mTOR inhibitory therapy [23].
Heart transplant patients receiving mTOR inhibitors together with calcineurin inhibitors also had more 
wound complications (OR 1.82, CI 1.15–2.87) [18]. A randomized study of 833 de novo kidney transplant  
recipi[INVESTIGATOR_58772] a higher rate of wound healing complications in the two everolimus groups compared to  
a control group receiving mycophenolate sodium [19]. Among 634 de novo heart transplant patients, 
wound infection  occurred in 6.7% of the 1.5 mg and 5.2% of the 3 mg everolimus groups; the rate was 
3.3% in the group treated with azathioprine in combination with cyclosporine and corticosteroids [20].  A 
subsequent study of everolimus in conjunction with cyclosporine in 176 cardiac transplant recipi[INVESTIGATOR_58773] a 6.6% wound infection rate [21]. Wound healing complications relating to surgical intervention 
were reported as serious adverse events in 8.0% of patients  receiving cyclosporine with everolimus and 
steroids in de novo heart transplant patients enrolled in a multicenter, randomized trial [22] Zuckerman  et 
al [22] studied risk factors associated with wound complications among  711 everolimus-treated patients 
who underwent heart transplantation:  12.3% had an incision-related wound  complication. Only BMI was 
significant in a multivariate analysis (12.9% increased odds for each 1 kg/m increase in BMI). They 
conclude that the overall risk for this complication is low, but increased in patients with increased  BMI  
[22]. They suggest that if a patient  is obese, diabetic, or needs  surgical re-exploration,  a higher surgical 
wound risk exists [22].  Similar findings have emerged from other solid organ transplant  studies.[23-25]
Everolimus: experience in patients with TSC
Everolimus is a  kinase inhibitor indicated with FDA approval for the treatment of:
• adults with  renal angiomyolipoma and TSC, not requiring  immediate surgery. The effectiveness of 
everolimus in the treatment  of renal  angiomyolipoma  is based on an analysis of durable  objective 
responses in patients treated for a median of 8.3 months. Further follow-up of patients  is required to 
determine long-term  outcomes.
• pediatric and  adult patients with TSC who have subependymal giant cell astrocytoma  (SEGA) that 
requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on 
demonstration of durable objective response, as evidenced by [CONTACT_58843]. 
Improvement in disease-related symptoms and overall survival in patients  with SEGA and TSC has not 
been demonstrated.
There is considerable  experience with everolimus  use in TSC patients. In a prospective, open-label trial of 
everolimus for SEGAs in 28 patients, everolimus was associated with few serious  side effects during the 
initial 6 months [8]. Self-limited upper respi[INVESTIGATOR_58774].  Four 
patients had serious adverse events during the 6-month trial but they were not clearly drug related: 
hospi[INVESTIGATOR_58775]  (n=2; one had a prior history of reactive airway disease; one also 
had grade 3 vomiting) and convulsion (n=2). Twenty-five of these patients continued on everolimus for  an 
average of 3 years and no new serious adverse events occurred [26]. A Phase  III, prospective,  double 
blind, randomized, multi-center study compared everolimus (n=78) and placebo (n=39) in TSC patients 
with radiologically enlarging SEGAs [27]. Everolimus  was given at 4.5 mg/m2/day and titrated to a level of 
5-15 ng/ml;  MRI scans were performed at 3, 6, and 12 months after initiating treatment. The investigators 
found that 27 of 78 patients (34.6%) receiving everolimus, versus none of the placebo group, had a 
significant response of > 50% reduction in tumor volume (p<0.0001) [27]. Everolimus was generally well 
tolerated. A subsequent long-term followup study of 28 patients enrolled, 25 were still under treatment at 
the time of analysis.[28] Median dose was 5.3 mg/m(2)/day and median treatment duration was 34.2 
months (range 4.7-47.1). At all time points (18, 24, 30, and 36 months), primary SEGA volume  was 
reduced by ≥30% from baseline (treatment response) in 65%-79% of patients. All patients reported ≥1 
adverse event  (AE), mostly grade 1/[ADDRESS_63916] commonly reported drug-related AEs were upper respi[INVESTIGATOR_58776] (85.7%), stomatitis (85.7%), sinusitis (46.4%), and otitis media (35.7%). No drug-related grade  
4 or 5 events occurred.[27a] In a larger, international multicenter study, 117 patients were randomly 
assigned to everolimus (n=78) or placebo  (n=39). 27 (35%) patients in the everolimus group  had at least  
50% reduction in the volume of SEGAs versus none in the placebo  group (difference 35%, 95% CI 15-52;  
p<0·0001).[29] Adverse  events were mostly grade  1 or 2; no patients discontinued treatment because of 
adverse events. The most common adverse events were mouth  ulceration (25 [32%] in the everolimus
Everolimus  ef fects on brain mTOR  and excitability
Version:  09/20/18Page 8
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58844]  [5%] in the placebo  group), stomatitis (24 [31%] vs eight [21%]),  convulsion (18 [23%]  vs ten
[26%]), and pyrexia (17 [22%] vs six [15%]).[29]
Other studies have  used rapamycin to treat angiomyolipomas over 12 months with good efficacy and 
safety [30]. Everolimus was approved to treat renal angiomyolipomas in TSC. The most common AE 
during the 48-week trial was stomatitis. The most common Grade 3-4 adverse reactions (incidence >= 
2%) were stomatitis, amenorrhea and convulsion. The most  common laboratory  abnormalities  (incidence
>= 50%) were hypercholesterolemia, hypertriglyceridemia and anemia. ([COMPANY_001] data on file. 
http://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf.  Accessed
 April 2012)
1.5 Dose Rationale and Risk/Benefits
The starting  dose of  everolimus for treatment patients  will be 4.5 mg/m2 once daily; adjust to attain trough 
concentrations of 5-15ng/ml.  The dose will be adjusted for co-medications as outlined in section 5.1.
However, these are  initial  doses often need to be titrated up to therapeutic everolimus serum levels  (5 – 
15 ng/mL). Since our everolimus treatment duration is 7-21 days and the half-life is 30 hours, the time to 
equilibration will be approximately 150 hours (6.25 days) and will not allow  the investigators to adjust 
dose to achieve therapeutic  levels in the initial groups  of patients who will be treated for one to two 
weeks. We will double the dose in our study  for patients who are taking an enzyme-inducing antiepi[INVESTIGATOR_58777] (EIAED)  since serum everolimus levels  will be lower due to increased hepatic metabolism.
After a minimum  of three patients are treated for one week, if there is no evidence of serious adverse  
effects and other dose-level tolerability and safety issues, we will extend the treatment duration by a 
maximum of one week. Again, after a minimum of three patients treated for two weeks without evidence 
of serious adverse effects and other dose-level tolerability  and safety  issues,  we will extend the treatment  
duration to three weeks. . For patients treated longer than two weeks, an everolimus blood level will be 
obtained after 10-[ADDRESS_63917] dose to maintain  a serum level of 5-10 ug/ml.
The most common adverse reactions (>30%) to everolimus treatment in TSC patients include stomatitis   
in patients with angiomyolipomas and stomatitis and respi[INVESTIGATOR_58778].  
Potential risks associated with 7-[ADDRESS_63918] been identified suffer  from chronic illness and treatment with 
other immunosuppressive agents. To reduce the potential risk to patients with TSC in our study, we will 
exclude patients  who are 1) obese, 2) over age 50, 3) have a history of chronic medical illness, or 4) 
treatment with an immunosuppressant (other than everolimus during the 7-day trial).  These criteria 
should minimize the potential for peri-operative infection or impaired wound healing. However, we will be 
vigilant with the Data Safety  Monitoring Plan to closely  assess all patients postoperatively and record all 
complications, including infection and impaired wound healing. Further, we will institute a special 
surveillance system to monitor for these potential side effects.
The following are  possible benefits  that could occur through this research study:
1)Elimination of need for epi[INVESTIGATOR_58779] a significant reduction in seizure  activity;
2)Improvement in  seizure control, as well as reduction of cognitive, behavioral, and physical 
injury, and sudden death risks associated with ongoing  seizures;
3)Improvement in cognitive or behavioral function; and
4)Reduction in signs and symptoms of TSC (e.g., renal  angiomyolipomas, 
lymphangiomyelotmatosis, facial angiofibromas).
5)Close medical follow-up care
Everolimus  ef fects on brain mTOR  and excitability
Version:  09/20/18Page [ADDRESS_63919] the potential benefits, which for the patients 
with TSC include: 1) elimination  of need for epi[INVESTIGATOR_58779] a significant reduction in seizure 
activity, 2) improvement in seizure control and reduction of cognitive, behavioral, physical injury, and 
sudden death risks associated with ongoing  seizures, 3) improvement in cognitive or behavioral  function, 
and 4) reduction in systemic signs and symptoms of TSC (e.g., renal angiomyolipomas, 
lymphangiomyelotmatosis, facial angiofibromas, etc.). For patients with FCD, the potential benefits  are 
likely less, but could include 1 through 3 above since abnormalities of mTORC1 signaling are 
documented in FCD and it remains uncertain if therapy may provide clinical  benefits.
2 Study Objectives
2.
1Primary Objective:
The
 primary objectives of  this pi[INVESTIGATOR_58780] 1) test the feasibility and safety  of recruiting patients  into a 
prospective study before  epi[INVESTIGATOR_58781],  and 2) test the 
hypothesis that everolimus therapy in TSC and FCD patients with TRE will reduce mTOR signaling 
(reduced S6 phosphorylation) as compared to TSC and FCD who did not receive everolimus  (control 
group).
2.2. Secondary Objectives:
The 
secondary objectives  include
1)systemic mTOR signaling suppression (VEGF-D) pre-and post-treatment,
2)genetic analysis of resected brain  tissue,
3)correlate blood everolimus levels with brain measures of S6  phosphorylation,
4)measure markers of cortical hyperexcitability (glutamate and GABA receptors, levels of 
neuroinflammation, axonal  abnormalities, myelination  defects) as compared to historical controls and
5)electrocorticographic (ECoG) recordings as compared to historical controls
[ADDRESS_63920] three patients.  This will   
be extended at one week intervals/three patient groups to a maximum treatment duration of 21 days.
Resected brain tissue will be analyzed for activation of mTORC1 and mTORC2 signaling  pathways,  
glutamatergic and GABA-ergic neurotransmission using histochemistry, genetic analysis, as well as 
extracellular field recordings  in acute ex-vivo brain slices from surgery.  A blood sample, collected  at the 
time of surgery, will be analyzed  for everolimus  levels and VEGF-D. All patients will undergo standardized 
intra-operative ECoG recordings over the primary epi[INVESTIGATOR_58782].
Subjects will be  in the study for approximately 10 weeks.  We will study variables listed in specific aims 1 
and 2 in TSC and FCD patients treated with 7 to 21 days of everolimus  and compare these to untreated 
control patients with TRE and TSC or FCD. A concurrent comparison group of 12 subjects will also be 
enrolled. They will all be undergoing routine surgery for the diagnosis of TRE with TSC or FCD.
All study procedures  will be performed at either the Comprehensive Epi[INVESTIGATOR_58783]  (CEC)  with the 
exception of the surgery, which will be performed  at Tisch Hospi[INVESTIGATOR_58784] y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 10
3.2 Primary Outcome Measures
The primary outcome  measures for  this study are to 1) test the feasibility  and safety  of recruiting patients  
into a prospective  study before epi[INVESTIGATOR_58781],  and 2) 
estimate S6 phosphorylation status  as a measure of downstream mTOR activity in patients treated with 
Everolimus as compared to 12 control subjects’ brain tissue (FCD and TSC patients who had epi[INVESTIGATOR_58785]) who had not received Everolimus.
3.3 Secondary Outcome  Measures
●Other  mTOR  downstream/upstream  markers in the brain (S6 phosophorylation) and peripheral  
VEGF-D levels.
●Blood and brain levels of cytokines (and TNF-α)  and inflammatory proteins  (HMGB1)at the time of 
surgery
●Brain glutamate and GABA receptor expression at the time of surgery
●Blood levels of everolimus at the time of  surgery
●Electrocorticography of minimum of [ADDRESS_63921] points. Extracellular field and 
recordings in acute ex-vivo brain slice: After resection, one brain sample will be immediately 
placed, under sterile conditions, into cold,  oxygenated  artificial cerebrospi[INVESTIGATOR_872] (ACSF). 
Tissue will be transported to the lab and, within 5-[ADDRESS_63922] Selection and Withdrawal
4.
1Inclusion Criteria (Active Group)
1.Female and male patients, age 2 years to 50 years.
2.Diagnosis: treatment resistant epi[INVESTIGATOR_002] (> 2 failed  anti-epi[INVESTIGATOR_58786] [AED] treatment regimens) 
and either:
●Tuberous Sclerosis Complex
●Focal Cortical Dysplasia on MRI or neuropathology from prior brain surgery
3.Diagnosis of TSC confirmed by [CONTACT_58845]/or  clinically definite diagnosis of TSC 
according to the modified Gomez criteria  [31]. Clinically definite diagnosis is defined as:
●Two Major Features,  or
●One Major Feature plus two Minor Features
4.Adequate bone marrow function as shown by: [CONTACT_58846]  ≥1.5 x 109/L, Platelets ≥100 x 109/L, Hb >9 
g/dL;
5.. Adequate liver function as shown  by
a.Total serum bilirubin ≤2.0 mg/dL,
b.ALT and AST ≤2.5x ULN (≤5x ULN in patients with liver metastases), 
c.INR ≤2; if applicable
6.Adequate renal function: serum creatinine ≤1.5x ULN;
7.Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤2.5x  ULN.if 
applicable NOTE: In case one or both of these thresholds are exceeded, the patient  can only be 
included after initiation of appropriate lipid lowering medication;
8.Signed informed consent obtained prior to any screening procedures.
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 11
4.1.1 Inclusion Criteria (Concurent Comparison Group)
1.Female and male patients, age 2 year to 50 years. Matched for age (+/- 7 years) and sex of 
subjects in the treatment group.
2.Diagnosis:  treatment  resistant  epi[INVESTIGATOR_002] (> 2 failed  anti-epi[INVESTIGATOR_32551] [AED] treatment regimens) 
due to TSC or FCD. Matched for diagnosis of TSC and FCD.
3.Brain surgery for seizure control in which  tissue is banked for research utilizing  an existing IRB- 
approved study.
4.2 Exclusion Criteria (Active  Group)
1.Treatment with an mTOR inhibitor (everolimus, sirolimus) during the past four  weeks.
2.Patients taking more than one strong CYP3A4 inducer will be excluded.
3.Known hypersensitivity to an mTOR inhibitor (everolimus, sirolimus)
4.Body mass index  (BMI) > 95% for age in individuals 17 years old or younger; BMI > 30 kg/m2 in 
individuals > 17 years old
5.Failure to establish diagnosis of treatment resistant epi[INVESTIGATOR_002] (i.e., adequate  trials of two 
appropriately-chosen, tolerated and adequate trials of antiepi[INVESTIGATOR_006]) [32].
6.Presence of mesial temporal  sclerosis  or other brain structural lesion  than those identified in TSC 
and FCD, other than incidental abnormalities (e.g., pi[INVESTIGATOR_58787])
7.Exposure to any investigational agent in the month prior to study  entry.
8.Women of child-bearing potential, defined as all women physiologically capable of becoming  
pregnant, unless they are using highly  effective methods of contraception during dosing  of study 
treatment. Highly effective contraception methods include combination of any two of the following  
(a+b or a+c or b+c):
a.Use of oral, injected or implanted hormonal methods of contraception or;
b.Placement of an intrauterine device (IUD) or intrauterine system (IUS);
c.Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault 
caps) with spermicidal foam/gel/film/cream/ vaginal  suppository;
d.Total abstinence or;
e.Male/female sterilization.
Women are considered post-menopausal  and not of child-bearing potential  if they have had 12 
months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g.  age 
appropriate, history of vasomotor symptoms) or have had surgical bilateral  oophorectomy (with or 
without hysterectomy) or tubal ligation at least six weeks prior to randomization. In the case of 
oophorectomy alone, only when the reproductive status of the woman has been confirmed by 
[CONTACT_58847]-bearing potential.
9.Male patients whose  sexual partner(s) are women of child-bearing potential who are not willing to 
use adequate contraception, during the study and for [ADDRESS_63923]
11.Patients will be excluded if using strong CYP3A4  inhibitors  (e.g., ketoconazole,  itraconazole, 
clarithromycin, atazanavir, nefazodone, saquinavir,  telithromycin, ritonavir, indinavir, nelfinavir, 
voriconazole).
12.History of malignancy patients who are receiving anti-cancer treatments,  such as radiation  therapy 
and/or chemotherapy.
13.Patients with severe and/or uncontrolled medical conditions, including but not limited to cardiac 
disease, cancer, disorders requiring immunosuppressive therapy, systemic autoimmune  disorders, 
or uncontrolled diabetes mellitus.
14.Patients on chronic corticosteroid  therapy
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page [ADDRESS_63924] received live 
attenuated vaccines. Examples of live attenuated  vaccines include intranasal  influenza,  measles, 
mumps, rubella, oral polio, BCG, yellow fever, varicella and TY21a typhoid  vaccines;
18. Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the 
absorption of oral everolimus;
19.Uncontrolled  diabetes mellitus as defined by [CONTACT_13505]1c >8% despi[INVESTIGATOR_58788]. Patients with 
a known  history of impaired fasting glucose or diabetes mellitus  (DM) may be included,  however 
blood glucose and antidiabetic treatment must be monitored closely throughout the trial and 
adjusted as necessary;
20.Patients who have any severe and/or uncontrolled medical conditions such as:
a.unstable  angina pectoris, symptomatic congestive heart  failure, myocardial infarction  ≤6 months 
prior to start of everolimus, serious uncontrolled cardiac arrhythmia, or any other clinically 
significant cardiac disease
b.Symptomatic congestive heart failure of [LOCATION_001] heart Association Class III or IV
c.active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, 
decompensated liver disease,  and chronic hepatitis (i.e. quantifiable HBV-DNA and/or positive 
HbsAg, quantifiable HCV-RNA),
4.2.1 Exclusion  Criteria  (Concurrent  Comparison  Group)
1.Treatment with an mTOR inhibitor (everolimus, sirolimus) during the past four weeks.
2.Known hypersensitivity to an mTOR inhibitor (everolimus, sirolimus)
3.Body mass index (BMI)  > 95% for age in individuals 17 years old or younger; BMI > 30 kg/m2 in 
individuals > 17 years old
4.Failure to establish diagnosis  of treatment resistant epi[INVESTIGATOR_002] (i.e., adequate  trials of two 
appropriately-chosen, tolerated and adequate trials of antiepi[INVESTIGATOR_006]) [31].
5.Presence of mesial temporal sclerosis or other brain structural lesion  than those  identified in 
TSC and FCD, other than incidental abnormalities (e.g., pi[INVESTIGATOR_58787])
6.Exposure to any investigational agent in the month prior to study entry.
7.Women of child-bearing  potential, defined as all women physiologically capable of becoming  
pregnant, unless they are using highly effective methods of contraception during dosing of 
study treatment. Highly effective contraception methods include combination of any two of the 
following (a+b or a+c or b+c):
a.Use of oral, injected or implanted hormonal methods of contraception or;
b.Placement of an intrauterine device or intrauterine system;
c.Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault 
caps) with spermicidal foam/gel/film/cream/ vaginal  suppository;
d.Total abstinence or;
e.Male/female sterilization.
Women are considered post-menopausal  and not of child-bearing potential  if they have had 12 
months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g.  age 
appropriate, history of vasomotor symptoms) or have had surgical bilateral  oophorectomy (with or 
without hysterectomy) or tubal ligation at least six weeks prior to randomization. In the case of 
oophorectomy alone, only when the reproductive status of the woman has been confirmed by 
[CONTACT_58847]-bearing potential.
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 13
8.Male patients whose sexual partner(s) are women of child-bearing potential who are not willing  
to use adequate contraception, during the study and for [ADDRESS_63925]
10.Patients will be excluded if using  strong  CYP3A4  inhibitors (e.g., ketoconazole,  itraconazole, 
clarithromycin, atazanavir, nefazodone, saquinavir,  telithromycin, ritonavir, indinavir, nelfinavir, 
voriconazole).
11.History  of malignancy patients who are receiving anti-cancer treatments,  such as radiation 
therapy and/or chemotherapy.
12.Patients with severe and/or uncontrolled medical  conditions, including but not limited to cardiac 
disease, cancer, disorders requiring immunosuppressive therapy, systemic autoimmune 
disorders, or uncontrolled diabetes mellitus.
13.Patients on chronic corticosteroid therapy
14.A history of HIV seropositivity
15.Known drug or alcohol use or dependence
16.Patients who have received live attenuated  vaccines  within [ADDRESS_63926] received live 
attenuated vaccines. Examples of live attenuated vaccines include intranasal influenza, 
measles, mumps, rubella, oral polio, BCG, yellow fever, varicella and TY21a typhoid vaccines;
17.Known impairment of gastrointestinal (GI) function or GI disease  that may significantly  alter 
the absorption of oral everolimus;
18.Uncontrolled  diabetes mellitus as defined by [CONTACT_13505]1c >8% despi[INVESTIGATOR_58788]. Patients 
with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, 
however blood glucose  and antidiabetic treatment must  be monitored closely  throughout  the 
trial and adjusted as necessary;
19.Patients who have any severe and/or uncontrolled medical conditions such as:
a.unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction  ≤6 
months prior to start of everolimus, serious uncontrolled  cardiac arrhythmia,  or any other 
clinically significant cardiac disease
b.symptomatic congestive heart failure of [LOCATION_001] heart Association Class III or IV
c.active (acute or chronic) or uncontrolled severe infection, liver disease  such as cirrhosis, 
decompensated liver disease, and chronic hepatitis (i.e. quantifiable HBV-DNA and/or 
positive HbsAg, quantifiable HCV-RNA),
4.[ADDRESS_63927] Recruitment, Screening, and Consenting
All patients  will be recruited,  consented and enrolled at the NYU Comprehensive Epi[INVESTIGATOR_58783] (CEC). 
The NYU CEC  is the ideal centers for recruitment since they already has a high influx of epi[INVESTIGATOR_58789]. All eligible subjects have treatment resistant epi[INVESTIGATOR_58790]. All patients who are identified 
as potential  candidates  for the study will be entered into a study screening log which  will document  the 
individual who referred the subject to the study or if they were self-referred and if the 
subject/parents/guardian did not participate why they declined or were not eligible,  and for those  who were 
ineligible, the specific reason why they were ineligible.
.
The physician will explain  the study during the routine visit and inform the subject and surrogate that a 
capacity assessment will be performed  to determine whether the subject is capable of providing  an 
informed decision to participate in the study. At this time, a capacity assessment will be conducted if the 
subject does not refuse the assessment. If there is already documentation  of lack of capacity,  no 
assessment will be needed. Patients who are eligible and are lacking in capacity will be allowed to 
participate  by  [CONTACT_58848]  a  parent/legal  guardian/health  care  proxy.  This  protocol      is
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page [ADDRESS_63928]/parent/legal  guardian/health  care proxy agrees, they will  be given the informed consent 
document and study personnel will be present  to explain  the study in further details the objectives and 
study procedures, risks and benefits. We will review the consent form documents with them and answer 
any questions they have. They will be given an opportunity to ask questions regarding the study and 
consent form. After all parties have signed off on the consent, we will give them a copy of the informed 
consent documents.
As the majority of our surgical patients reside outside of the NYC area, there may be circumstances in 
which patients are unable to be present at the study  site for consenting  due to distance and travel issues.  
In such cases, the informed consent will be faxed or emailed to the patient.  The principal investigator [INVESTIGATOR_58791]. The principal investigator [INVESTIGATOR_58792]. The patient will then sign and date the informed  
consent and return it to the principal investigator [INVESTIGATOR_58793]. Once received the principal investigator 
[INVESTIGATOR_58794]. A copy of this signed and dated informed consent will then be 
faxed or emailed to the patient before beginning any study procedures.  The patient will also bring the 
original signed informed consent to the study site at the first visit to again be signed by [CONTACT_1961]. Both the mailed informed consent  and the original will be kept on file and copi[INVESTIGATOR_58795].  All phone correspondence and mailings will be documented  in the study file. Telephone  
consent is necessary for these long distance subjects who will be coming in for a combined visit [ADDRESS_63929]  is 18 years old and it has been determined that he/she has capacity, he/she will review and 
sign an informed consent. The study  personnel will be present to explain the study in further  details and 
answer questions  as needed. After all parties have signed off on consent,  a copy of the informed consent 
documents will be given to the subject.
Assent by [CONTACT_58849]  7-17 years old and it has been determined that he/she  has capacity,  he/she will review 
and sign an assent form. In addition, if the parent/legal  guardian/health care proxy agrees, they will be 
given the informed consent document and study personnel will be present  to explain in further  details the 
study the objectives  and study procedures, risks and benefits. After all parties have signed off on assent 
and consent, a copy of the informed assent and consent documents will be given to the subject and the 
subject’s parent/legal guardian/health care proxy.
Consent by [CONTACT_58850] (for subjects lacking capacity)
If the subject assents, and the parent/legally authorized representative agrees, they will be given the  
informed consent  document and study personnel will be present to explain in further details the study the 
objectives and study procedures,  risks and benefits.  Legally authorized representative  will be identified as 
per [LOCATION_001] state law. The consent form will be reviewed and any questions they may have regarding 
the study and consent form will be answered. After all parties have signed off on the consent, a copy of 
the informed consent documents will be given to  them.
Assessment
A capacity assessment will be conducted by [INVESTIGATOR_124]. Manisha Holmes, (NYU CEC) who is independent of the 
study to ensure the patient’s level of capacity. She is delegated only to perform capacity assessment 
throughout the study. See is board certified Neurologist as well as a Epi[INVESTIGATOR_58796] y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 15
experienced in dealing with patients with drug resistant epi[INVESTIGATOR_002]. Capacity will be assessed through  
neurological examinations and neuropsychology  reports conducted by [CONTACT_58851]/or development delays that have been documented.
For long distance subjects, [CONTACT_58876] will interview the parent and child via a speaker phone if the child  
is verbal. If the child is nonverbal they will be considered incapable of capacity to consent. For those that 
are verbal, [CONTACT_58876] will determine if the child is able  to:
a)communicate  clearly in English (or another language with translation services),
b)grasp the fundamental meaning of information that is communicated,
c)acknowledge medical condition and likely consequences of involvement in the study, 
and d) engage in a rational process of manipulating relevant  information.
4.[ADDRESS_63930] may withdraw from the study due to:
1)Improvement in  seizure activity to an extent that the patient  and/or parents/legal guardians  elect to 
forego epi[INVESTIGATOR_58797],
2)Difficult complying with protocol requirements  or
3)A decision  to withdrawal  for personal reasons or adverse effects that are less severe than those that 
lead to mandatory discontinuation of the treatment phase.
A subject will be  withdrawn  from the study if any of the following are present:
1)The subject develops a systemic bacterial or fungal infection.
2)The subject develops a CTAE grade 3 or 4 (severe) event.
3)The patient  and study  will be terminated if he or she is the second case of impaired surgical wound 
healing or the third case of serious infection, including infection of the wound site, among the [ADDRESS_63931] date 
they take the medication (or as close). We will also collect all safety data and seizure activity  calendars. 
Since these patients  will be entered into the study only [ADDRESS_63932] complete study records.
5 Study Drug
Everolimus 
will be supplied by [CONTACT_58852].
5.1 Description & Packaging
Everolimus 
(RAD001) is an inhibitor of mTOR, and is FDA-approved as an antineoplastic agent. The 
chemical name [CONTACT_24498] (1R, 9S,12S,15R,16E,18R,19R, 21R,  23S, 24E, 26E, 28E,30S, 32S,
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 16
35R)-1,18- dihydroxy-12-{(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}- 
19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[[IP_ADDRESS],9]hexatriaconta-
 
16,24,26,28-tetraene-2,3,10,14,20-pentaone. The molecular formula is C53H83NO14 and the molecular 
weight is 958.2.
For this study, everolimus  will be supplied as dispersal tablets of 2.0, 3.0, 5.0 mg strength. The drug will 
be supplied  by [CONTACT_58853] 4.5 mg/m2 once daily; adjust to attain trough 
concentrations of 5-15ng/ml. The dose will be adjusted for co-medications as outlined in the section 
immediately below.
.
CYP3A4 and/or P-glycoprotein (PgP) Inhibitors
Patients will be excluded if using strong CYP3A4 inhibitors (e.g., ketoconazole,  itraconazole,  
clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir,  nelfinavir, 
voriconazole). If the patient is receiving a co-administered drug with moderate CYP3A4 and/or PgP 
inhibitors (e.g., amprenavir,  fosamprenavir, aprepi[INVESTIGATOR_053], erythromycin,  fluconazole,  verapamil,  diltiazem), 
the everolimus dose will be reduced by [CONTACT_3450] 50% to maintain trough  concentrations of 5 to 10 
ng/mL. If dose reduction is required for patients  receiving 2.[ADDRESS_63933] on everolimus 
for sufficient duration. No moderate or strong CYP3A4 and/or PgP inhibitor will be added or discontinued 
during the study period.
Patients taking one concomitant strong CYP3A4 inducer for seizure control (e.g., phenytoin, 
carbamazepi[INVESTIGATOR_050], phenobarbital) will be allowed in the study. Patients taking more than one r strong 
CYP3A4 inducer will be excluded. For patients requiring a concomitant strong CYP3A4 inducer (an 
Enzyme-Inducing Antiepi[INVESTIGATOR_49854] (EIAED), we will double the everolimus dose from that prescribed in 
Table 2. Subsequent dosing  should  be individualized based  on therapeutic drug monitoring if the patient 
is treated with everolimus  for sufficient duration. No EIAED will be discontinued  during the study.
Preparation of the everolimus dispersal:
The patient will receive everolimus tablets for oral suspension as a suspension only. The everolimus 
tablets for oral suspension will be administered orally once daily at the same time every day. It will be 
given either consistently with food or consistently without food. The suspension will be administered 
immediately after preparation. The suspension  will be discarded if not administered within  60 minutes 
after preparation.
Prepare suspension in water only. 
Using an oral syringe:
• Place  the prescribed dose  of everolimus tablets for oral suspension  into a 10-mL syringe. Do not exceed 
a total of 10 mg per syringe.
If higher doses  are required, prepare an additional syringe. Do not break or crush tablets.
• Draw approximately 5 mL of water and 4 mL of air into the syringe.
•
Place  the filled  syringe into a container (tip up) for 3 minutes,  until the everolimus tablets  for oral 
suspension are in suspension.
• Gently invert the syringe 5 times immediately prior to administration.
•
After administration  of the prepared suspension, draw approximately 5 mL of water and 4 mL of air into 
the same syringe,  and swirl the contents  to suspend remaining particles.  Administer the entire  contents of 
the syringe.
Using a small drinking glass:
•
Place  the prescribed dose  of everolimus tablets for oral suspension  into a small drinking  glass 
(maximum size 100 mL) containing
approximately 25 mL  of water. Do not exceed  a total of 10 mg of everolimus tablets  for oral suspension 
per glass. If higher doses are required, prepare an additional  glass. Do not break or crush tablets.
• Allow 3 minutes for suspension to  occur.
•
Stir the contents gently with a spoon, immediately prior to  drinking.
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 17
• After administration of the prepared suspension, add 25 mL of water
Everolimus
 tablets  for oral  suspension should NOT be taken with grapefruit or Seville orange juice or with 
other effectors  of CYP3A4  (other  than known  AEDs or other medications identified at Visit 1 as one of 
their baseline  medications).
NOTE: Everolimus should  be opened only at the time of administration as drug is both hygroscopic and 
light-sensitive.
5.2 Treatment Regimen
Everolimus 
will be self-administered (by [CONTACT_58854] 7-21 days prior to 
neurosurgery). The investigator  will instruct the patient to take the study drug exactly as specified in the 
protocol.
Patients who are eligible for the active treatment group with TSC or FCD only will receive everolimus. 
After a minimum of three patients are treated for 7 days (Table 2), if there is no evidence of serious 
adverse effects or other dose-level tolerability  and safety  issues, we will extend  the treatment  duration by 
a maximum of one week. Again, after a minimum of three patients are treated for two weeks without 
evidence of serious  adverse effects or other  dose-level tolerability and safety issues,  we will extend  the 
treatment duration to three weeks. . For patients treated longer than two weeks, an everolimus  blood 
level will be obtained after 10-[ADDRESS_63934] dose to maintain  a serum level of 5-10 ug/ml.  to 
revisit escalation and numbers If one patient at a dose duration has a serious  adverse effect during a 
treatment cohort period (e.g., 7 days), then up to [ADDRESS_63935] 3 patients.
Table 2: Dosing Escalation for Serial Cohorts
Serial 
Cohort 
NumberMinimum # of  
patients if no 
Grade 3 or 4 
adverse event  
or serious 
adverse 
eventsMinimum # of  
patients if one 
Grade 3 or 4 
adverse event  
or serious 
adverse 
events^Duration of 
everolimus
 
therapyResult of  one 
serious adverse
 
events including 
wound healing 
problem and 
serious infectionResult of two serious  
adverse events 
including wound 
healing problem and 
serious infection
1 3 9 7 days
2 3 6 14 days Add additional 
patients 
to Cohort 1Return to cohort one,  
no potential for longer  
treatment duration
3 1-3 6 21 days Add additional 
patients 
to Cohort 2Return to cohort  two, 
no potential for longer  
treatment duration
^ Adverse events as defined by [CONTACT_58855] v.4.0
Dosing:
●Patients NOT taking EIAEDs or other drugs know to inhibit or induce CYP34A or PgP: The 
dose will be administered according to the criteria in Section  5.1.
●Patients taking EIAEDs: The dose will be administered according to criteria in Section  5.1.
●Patients taking moderate CYP3A4  and/or PgP inhibitors:  The dose will be administered 
according to criteria in Section 5.1.
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 18
Dose adjustments  will be  permitted based on safety findings or serum everolimus  levels for patients  on 
treatment for 3 or 4 weeks.  A detailed explanation of permitted  dose adjustments  and the process that will 
be implemented are found in Section 5.3.1 Dose Adjustments.
5.3 Study Drug Administration
Patients will be instructed  to take  the prescribed dose of everolimus (or no treatment in the comparison 
group) orally  with a glass of water at regular intervals,  and each taken dose should  be at the same time in 
the morning after a light, nonfat breakfast. Body Surface Area (in m2) should be calculated using the 
following formula where weight (W) is in kilograms  and height (H) is in centimeters  *(Dubois and Dubois,  
1916): BSA= (W 0.425  x H0.725) x 0.007184. The dose will be 4.5 mg/m2 once daily; adjust to attain 
trough concentrations of 5-15ng/ml and exceptions for patients taking EIAEDs  based on section 5.1.
Subjects will take the medication as specified in Section 5.1.
Dietary habits around  the time of everolimus intake should be as consistent as possible  throughout the 
study, and in particular, on the day when sample is being taken for pharmacokinetic  analysis.
NOTE: Everolimus should NOT be taken with grapefruit or Seville orange juice. Patients with taking drugs 
that inhibit or induce CYP3A4 /450 or P-glycoprotein (P-gp) will be identified and doses adjusted  for   
those who are taking EIAEDs.
Patients will receive  treatment with  study drug for 7 to 21days or until the occurrence of unacceptable 
toxicity as defined by [CONTACT_58856], or if a Grade 3 or 4 Adverse  Event occurs as defined by 
[CONTACT_58857] (CTAE) v.4.[ADDRESS_63936] of the patient. Interruption for toxicity will lead to discontinuation of 
the medication.
Overall, safety data available from completed, controlled and uncontrolled  studies indicate that 
everolimus is generally well tolerated at weekly or daily dose schedules. The safety profile is 
characterized by [CONTACT_58858] (AEs). These AEs are generally reversible and non- 
cumulative.
5.3.1 Management of specific toxicities:
Overall, safety data available from completed, controlled and uncontrolled  studies indicate that 
everolimus is generally well tolerated at weekly or daily dose schedules. The safety profile is 
characterized by [CONTACT_58858] (AEs). These AEs are generally reversible and non- 
cumulative.
Adverse events most frequently observed with everolimus are rash, stomatitis/oral mucositis, non- 
infectious pneumonitis, fatigue, headache, anorexia, nausea, vomiting, diarrhea, and infections.  Overall, 
the most frequently observed laboratory abnormalities include  neutropenia,  thrombocytopenia, 
hypercholesterolemia, and/or hypertriglyceridemia. The majority of these AEs have been of mild to 
moderate severity  (NCI CTC grade 1-2). Recommendations for dose adjustments for non-hematologic 
and hematologic adverse  events are summarized in Tables 3 and 4.
Table 3: Dosing  guidelines  for Everolimus-related non-hematologic  toxicities
C O N F ID E N T IA L
T hi s d o c u m e n t a n d i nf or m ati on is  t he pr o p ert y o f t he N Y U  S c h o ol o f M e di ci n e  a nd L a n g o n e  M e di c al  C e nt er.  Do  n ot di s cl o se  or u s e 
e x c e p t as a ut h ori z e d  in writi n g b y t he  st u d y I ND s p o n s orE v er oli m u s  eff e ct s  on br ai n  m T O R  a nd e x cit a bilit y
V er si o n :  0 9/ 2 0/ 1 8P a g e 1 9
T o xi cit y A cti o n
A S T or  A L T el e v ati o n
Gr a d e 1  ( > U L N - 3. 0 x U L N)  
Gr a d e 2 ( > 3. 0 - 5. 0 x  U L N)
A S T or  A L T el e v ati o n  
Gr a d e 3 ( > 5. 0 - 2 0. 0  U L N)*
A S T or  A L T el e v ati o n  
Gr a d e 4 ( > 2 0 x  U L N)*
R e c urr e n c e of  gr a d e 4 aft er d o s e  
r e d u cti o n or t o xi cit y r e q uiri n g 
E v er oli m u s i nt err u pti o n f or >  [ADDRESS_63937] er ol e mi aM ai nt ai n c urr e nt  d o s e l e v el
I nt err u pt E v er oli m u s a d mi ni str ati o n u ntil r e s ol uti o n t o ≤  gr a d e 1 
( or ≤  gr a d e 2 if b a s eli n e v al u e s w er e wit hi n t h e r a n g e of gr a d e  
2). If r e s ol uti o n o c c ur s ≤  [ADDRESS_63938] art e d 
at t h e d o s e l e v el pri or t o  i nt err u pti o n.
If r e s ol uti o n t a k e s > 7 d a y s, or if e v e nt r e c ur s wit hi n 2 1 d a y s,  
h ol d E v er oli m u s u ntil r e c o v er y t o ≤  gr a d e 1 or b a s eli n e gr a d e /  
v al u e a n d r ei ntr o d u c e E v er oli m u s at o n e d o s e l e v el l o w er,  if 
a v ail a bl e.
I nt err u pt E v er oli m u s a d mi ni str ati o n  u ntil r e s ol uti o n t o ≤  gr a d e 1 
( or ≤  gr a d e 2 if b a s eli n e v al u e s w er e wit hi n t h e r a n g e of gr a d e  
2). If r e s ol uti o n o c c ur s ≤  [ADDRESS_63939] art e d 
at  o n e  d o s e  l e v el l o w er. If r e s ol uti o n t a k e s >  7  d a y s,  di s c o nti n u e  
E v er oli m u s.
Di s c o nti n u e  E v er oli m u s.
I nt err u pt E v er oli m u s a d mi ni str ati o n u ntil r e s ol uti o n t o ≤  gr a d e 1 
or b a s eli n e gr a d e /  v al u e.
If r e s ol uti o n o c c ur s wit hi n ≤  [ADDRESS_63940] art e d at t h e d o s e l e v el pri or t o  i nt err u pti o n.
If r e s ol uti o n t a k e s > 7 d a y s, or if e v e nt r e c ur s wit hi n 2 1 d a y s,  
h ol d E v er oli m u s u ntil r e c o v er y t o ≤  gr a d e 1 or b a s eli n e gr a d e /  
v al u e a n d r ei ntr o d u c e E v er oli m u s at o n e d o s e l e v el l o w er,  if 
a v ail a bl e.
P ati e nt s  will  b e  wit h dr a w n  fr o m t h e st u d y  if t h e y f ail t o r e c o v er t o
  gr a d e  1  or  b a s eli n e  gr a d e  / v al u e  wit hi n  2 1  d a y s.
A n y ot h er gr a d e  4 H ol d  E v er oli m u s  u ntil  r e c o v er y t o gr a d e    1  or  b a s eli n e  v al u e 
R ei ntr o d u c e  E v er oli m u s  at  o n e  d o s e  l e v el l o w er, if a v ail a bl e.
Gr a d e 3  or 4 cli ni c al li v er f ail ur e 
( a st eri xi s or e n c e p h al o p at h y/ c o m a)
R e c urr e n c e of  i nt ol er a bl e gr a d e 2 
m u c o siti s or gr a d e 3 e v e nt  aft er  
d o s e  r e d u cti o n
R e c urr e n c e of  gr a d e 4 aft er d o s e  
r e d u cti o n
A n y n o n- h e m at ol o gi c  t o xi cit y 
r e q uiri n g E v er oli m u s i nt err u pti o n 
f or > [ADDRESS_63941] b e di s c o nti n u e d.
Di s c o nti n u e  E v er oli m u s  
Di s c o nti n u e  E v er oli m u s
T a bl e  4:  D o si n g  g ui d eli n e s  f or E v er oli m u s-r el at e d  h e m at ol o gi c  t o xi citi e s
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 20
Toxicity Action
Grade 1 thrombocytopenia 
(platelets 
0-75, ≥ 75 x109/L)
Grade 2 thrombocytopenia (platelets
<75, ≥ 50x109/L)
Grade 
3 thrombocytopenia (platelets
<50,) OR
Grade 
4 thrombocytopenia (platelets
< 
25 x109/L)
Grade 3 neutropenia or anemia  
(neutrophil <1, ≥0.5 x109/L)No action.
Temporary dose interruption until recovery to Grade ≤1.
    Re-initate treatment at the same dose.
Interrupt Everolimus  until resolution  to grade  ≤1
Re-initate treatment at a lower dose.
     Interrupt  Everolimus until  recovery to grade ≤2. Then  
     reintroduce Everolimus at the same dose.
Grade 4 neutropenia or anemia      Interrupt Everolimus until recovery to grade  ≤2. Then 
 reintroduce Everolimus at a lower dose.
Febrile neutropenia Interrupt Everolimus  until resolution to grade 1 (or baseline 
value) and no fever. Reintroduce Everolimus at one dose 
level lower, if available.*
Recurrence of grade 3 toxicity after 
dose reduction
*Recurrence of grade 4 toxicity 
(including febrile neutropenia) after 
dose reduction
*Any hematologic toxicity  requiring  
Everolimus interruption for > [ADDRESS_63942] possible dose level of Everolimus  is 5 mg every other 
day (2.5 mg daily). Below this level, Everolimus must be 
discontinued.
Discontinue Everolimus
Discontinue Everolimus
C O N F ID E N T IA L
T hi s d o c u m e n t a n d i nf or m ati on is  t he pr o p ert y o f t he N Y U  S c h o ol o f M e di ci n e  a nd L a n g o n e  M e di c al  C e nt er.  Do  n ot di s cl o se  or u s e 
e x c e p t as a ut h ori z e d  in writi n g b y t he  st u d y I ND s p o n s orE v er oli m u s  eff e ct s  on br ai n  m T O R  a nd e x cit a bilit y
V er si o n :  0 9/ 2 0/ [ADDRESS_63943] o m atiti s / or al m u c o siti s / m o ut h  ul c er s
P ati e nt s wit h  a cli ni c al hi st or y of st o m atiti s/ m u c o siti s/ m o ut h ul c er s a n d t h o s e wit h g a str oi nt e sti n al  
m or bi dit y a s s o ci at e d wit h m o ut h/ d e nt al i nf e cti o n s, irrit ati o n of e s o p h a g e al m u c o s a e. g.  
g a str o e s o p h a g e al  r efl u x di s e a s e ( G E R D) a n d pr e- e xi sti n g st o m atiti s/ m u c o siti s m u st b e m o nit or e d e v e n 
m or e  cl o s el y. P ati e nt s s h o ul d b e i n str u ct e d t o r e p ort t h e fir st o n s et of b u c c al m u c o s a irrit ati o n/r e d d e ni n g 
t o t h eir  st u d y p h y si ci a n  i m m e di at el y.
St o m atiti s/ or al  m u c o siti s/ m o ut h  ul c er s  d u e  t o e v er oli m u s  s h o ul d  b e  tr e at e d u si n g  l o c al s u p p orti v e  
c ar e. Pl e a s e  n ot e  t h at i n v e sti g at or s i n e arli er  tri al s h a v e  d e s cri b e d  t h e or al  t o xi citi e s a s s o ci at e d  wit h  
e v er oli m u s  a s m o ut h ul c er s, r at h er t h a n m u c o siti s or st o m atiti s. If y o ur e x a mi n ati o n r e v e al s m o ut h ul c er s 
r at h er t h a n a m or e g e n er al i nfl a m m ati o n of t h e m o ut h, pl e a s e cl a s sif y t h e a d v er s e e v e nt a s s u c h. W e 
will f oll o w  t h e p ar a di g m b el o w f or tr e at m e nt of st o m atiti s/ or al m u c o siti s/ m o ut h  ul c er s:
1 .F or mil d t o xi cit y ( gr a d e 1), u s e c o n s er v ati v e m e a s ur e s s u c h a s n o n- al c o h oli c m o ut h w a s h or  
s alt w at er ( 0. 9 %) m o ut h w a s h s e v er al ti m e s a d a y u ntil  r e s ol uti o n.
2 .F or  m or e  s e v er e  t o xi cit y ( gr a d e 2)  i n w hi c h  c a s e  p ati e nt s  h a v e  p ai n  b ut  ar e  a bl e  t o m ai nt ai n  
a d e q u at e  or al ali m e nt ati o n ( s e e T a bl e 5), m a n a g e wit h t o pi c al  a n al g e si c  m o ut h  tr e at m e nt s (i. e., 
l o c al a n e st h eti c s  s u c h a s, b e n z o c ai n e, b ut yl a mi n o b e n z o at e, t etr a c ai n e h y dr o c hl ori d e, m e nt h ol, 
or p h e n ol) wit h  or  wit h o ut  t o pi c al c orti c o st er oi d s,  s u c h  a s  tri a m ci n ol o n e or al  p a st e  0. 1 %  
( K e n al o g i n Or a b a s e®). T e m p or aril y i nt err u pt d o s e u ntil r e c o v er y t o Gr a d e ≤ 1.   R e-i niti at e 
Afi nit or® at t h e s a m e d o s e.   If st o m atiti s r e c ur s at Gr a d e 2, i nt err u pt d o s e u ntil r e c o v er y t o 
Gr a d e ≤ 1.   R e-i niti at e Afi nit or®at a l o w er d o s e.  
3 .F or gr a d e 3 i n w hi c h c a s e p ati e nt s c a n n ot m ai nt ai n a d e q u at e  or al ali m e n ati o n, m a n a g e wit h 
t o pi c al a n al g e si c  m o ut h  tr e at m e nt s (i. e., l o c al a n e st h eti c s  s u c h a s, b e n z o c ai n e, b ut yl 
a mi n o b e n z o at e, t etr a c ai n e h y dr o c hl ori d e, m e nt h ol, or p h e n ol) wit h  or  wit h o ut  t o pi c al 
c orti c o st er oi d s,  s u c h  a s  tri a m ci n ol o n e or al  p a st e  0. 1 %  ( K e n al o g i n Or a b a s e®). T e m p or aril y 
i nt err u pt d o s e u ntil r e c o v er y t o Gr a d e ≤ 1 .  R e-i niti at e Afi nit or® at a l o w er d o s e.
[ADDRESS_63944] o g e n  p er o xi d e,  i o di n e, a n d  t h y m e d eri v ati v e s  m a y  t e n d t o w or s e n  
m o ut h ul c er s. It i s pr ef er a bl e t o a v oi d t h e s e  a g e nt s.
T a bl e  5:  Tr e at m e nt  f or P ati e nt s  wit h  I nt ol er a bl e Gr a d e  2  M u c o siti s  
I nt ol er a bl e gr a d e 2 m u c o siti s I nt err u pt e v er oli m u s  a d mi ni str ati o n  u ntil  r e s ol uti o n t o ≤  gr a d e  1
 or b a s eli n e gr a d e / v al u e.
If r e s ol uti o n o c c ur s wit hi n ≤  [ADDRESS_63945] art e d at t h e d o s e l e v el pri or t o  i nt err u pti o n.
If r e s ol uti o n t a k e s > 7 d a y s, or if e v e nt r e c ur s wit hi n 2 1 d a y s,  
h ol d e v er oli m u s u ntil r e c o v er y t o ≤  gr a d e 1 or b a s eli n e gr a d e /  
v al u e a n d r ei ntr o d u c e e v er oli m u s at o n e d o s e l e v el l o w er,  if 
a v ail a bl e.
P ati e nt s  will  b e  wit h dr a w n  fr o m t h e st u d y  if t h e y f ail t o r e c o v er t o
  gr a d e  1  or  b a s eli n e  gr a d e  / v al u e  wit hi n  [ADDRESS_63946] e d s u p p orti v e  m e a s ur e s  at  t h e di s cr eti o n  of  t h e i n v e sti g at or: or al  mi n o c y cli n e,  t o pi c al 
t etr a c y cli n e, t o pi c al cli n d a m y ci n, t o pi c al sil v er s ulf a di a zi n e, di p h e n h y dr a mi n e, or al pr e d ni s ol o n e ( s h ort 
c o ur s e),  t o pi c al c orti c o st er oi d s, or  pi m e cr oli m u s.
5 .3 .1 .3 . M a n a g e m e nt of  di arr h e a
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page [ADDRESS_63947] onset (for example 4 mg orally followed by 2 mg orally 
every 2 hours until resolution of diarrhea).
[IP_ADDRESS]. Management of hyperlipi[INVESTIGATOR_58798]-treatment status and dietary habits of 
the patient. Grade  2 or higher hypercholesterolemia (>300 mg/dL or 7.75 mmol/L) or grade  2 
hypertriglyceridemia or higher  (>2.5x upper normal limit) should  be treated  with a 3-hydroxy-3-
methyl- glutaryl (HMG)-CoA reductase inhibitor (e.g. atorvastatin, pravastatin, fluvastatin) or appropriate 
triglyceride-lowering medication, in addition to diet.
Note: Concomitant therapy  with fibrates and an HMG-CoA reductase inhibitor is associated with 
an increased risk of a rare but serious  skeletal  muscle toxicity  manifested  by [CONTACT_090],  
markedly elevated  creatine  phosphokinase (CPK) levels and myoglobinuria, acute  renal failure and 
sometimes death. The risk versus benefit of using this therapy should be determined for individual 
patients based on their risk of cardiovascular complications of hyperlipi[INVESTIGATOR_035].
Hyperglycemia has been  reported  in clinical trials.  Monitoring of fasting  serum glucose  is 
recommended prior to the start of everolimus and periodically thereafter. Patients with diabetes mellitus 
will be excluded  from the study.
[IP_ADDRESS] Management of infections
Everolimus has immunosuppressive properties and may predispose patients to bacterial, fungal, viral or 
protozoal infections, including infections with opportunistic pathogens. Localized and systemic infections, 
including pneumonia, other bacterial infections, invasive fungal infections, such as aspergillosis or 
candidiasis and viral infections including reactivation of hepatitis B virus, have been described in patients 
taking everolimus. Some of these infections have been severe (e.g. leading to respi[INVESTIGATOR_58799]) and occasionally  have had a fatal outcome.
Physicians and patients  should be aware  of the increased risk of infection with everolimus. Treat pre- 
existing infections  prior to starting treatment with everolimus. While taking everolimus,  be vigilant for 
symptoms and signs of infection; if a diagnosis of infection is made, institute  appropriate treatment 
promptly and consider interruption or discontinuation  of everolimus.
If a diagnosis of invasive systemic fungal infection is made, discontinue everolimus and treat with 
appropriate antifungal therapy.
5.3.2 Dose Adjustments
There 
only planned dose adjustments will be in patients taking the drug for 3.  Patients will be started on    
a set dose of everolimus based on their BSA (m2) and whether  or not they are taking an EIAED. For those 
subjects taking everolimus for 3 weeks, a serum level will be obtained between days 10-12.  If the result  
is in desired range (5-10 ng/ml) for patient receiving study medication, the recommendation will be no 
change. If the value is between 3-5 ng/ml, the dose will be increased by 2.0 mg/m2/day and if the value is 
less than 3 ng/ml, the recommendation will be dose will be increased by 3.0 mg/ m2/day. If the value  is 
between 10-13 ng/ml, the dose will be decreased by 2.0 mg/m2/day. If the value is above 13 ng/ml, the 
dose will be decreased by 3.0 mg/m2/day.
5.3.3 Serum drug levels
The target range for everolimus serum levels in this study is between 5-10 mg/ml. For patients taking  
everolimus
 for [ADDRESS_63948] Barnabas will only enroll  controls
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page [ADDRESS_63949].Doyle will also review  their patient’s charts to ensure they meet  the inclusion  criteria (review 
section 4.1 for all inclusion criteria). Once an eligible patient is decided upon, it will be presented to  the 
patient if they would like to participate in this study. Anyone who declines at the NYU CEC will be asked 
to be take part in the control part of the study. Therefore it is up the patient to choose whether or not they 
will participate in the study  and if they would like to  be a part of the intervention or the control group.
The objective of this study is to show that everolimus can suppress mTOR signaling in patients. A  control 
group is necessary for this study to compare  the mTOR with patients who do not take the everolimus.
Subject Compliance Monitoring
Patients should  be requested  to bring  their unused study drug and packaging to the clinic at each visit. 
Compliance should be verified by [CONTACT_093]’s staff through counting the number of tablets 
consumed between at the end of the study period.
5.4 Prior and Concomitant Therapy
Data will be collected on detailed information on all concomitant medical and over-the-counter  
medications 
taken by [CONTACT_13935]. The dosage and time(s) of administration will be recorded at the start 
of the study and throughout the study period. For patients taking an EIAED or moderate CYP3A4 and/or 
PgP inhibitors, the dose of everolimus will be adjusted as specified in section 5-2.
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 24
Patients are permitted to take their regular medications for epi[INVESTIGATOR_002], including rescue medications (e.g., 
rectal Diastat, oral clonazepam) during the study period. Patients are also permitted to take medications for 
medical conditions that are not exclusionary (e.g., propranolol for migraine will be permitted but prednisone 
for systemic lupus erythematosus will NOT be allowed). Patients are not permitted to take 
immunosuppressive drugs (other  than everolimus as a blinded medication)  during the study period.
Patients will be  asked to avoid drugs known to affect  coagulation or platelet adhesion for [ADDRESS_63950] be performed  and a drug receipt log filled 
out and signed by [CONTACT_17247].  The designated study staff will count and verify 
that the shipment contains all the items noted in the shipment inventory. Any damaged or unusable study 
drug in a given shipment (active drug or comparator) will be documented in the study files. The 
investigator must notify study sponsor of any damaged or unusable study treatments that were supplied  
to the investigator’s  site.
5.6.2 Storage & Handling
Study drug must  be stored at 25°C (77°F); excursions permitted between  15°–30°C (59°–86°F); protect  
from light and moisture. Procedures for proper handling and disposal  of anticancer drugs should be 
considered.
5.6.[ADDRESS_63951] be recorded in the source document. The patient will return all unused study drug at each 
dispensing visit and at the end of the study
At the completion of the study, there will be a final reconciliation of drug shipped, drug consumed, 
and drug remaining. This reconciliation will be logged on the drug reconciliation form, signed and 
dated. Any discrepancies noted will be investigated, resolved, and documented prior to return  or 
destruction of unused study drug. Drug destroyed on site will be documented in the study files.
6 Study Procedures
5.
7Visit 1 (Active/Control Patients)
NOTE
: This visit will  occur within 6 weeks of Visit 2, which  will be when patient  will be entered  into the 
study.
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page [ADDRESS_63952],  and/or  as applicable the subject’s parents or guardian:
●A detailed review  of the research subject’s medical  records and interview  to ensure that the 
subject meets inclusion criteria and does NOT meet any of the exclusionary criteria.
●History of current  seizure types and frequencies, concomitant medical  or psychiatric disorders,  
and all prescribed and over-the-counter medications taken.
●Complete review of systems.
●Subject physical  examination, including recording of vital signs, including height  and weight  to 
compute body mass index (BMI; see above) and body surface area (BSA), and neurological 
examination.
●Subject will be instructed to begin a daily seizure  diary today  that will be maintained and collected 
at the next visit.
5.8 Visit 2  – (Active patients- ‘NOTE:  This visit will occur 7-21 days before  surgery;  
patients/caretakers will be given Everolimus. )
The following activities  will  be conducted and research subject  information  will be collected  by [CONTACT_58859], and/or  as applicable the subject’s  parents or guardian:
●Recent  history will be reviewed  for any change in their medical status or change  in intake of 
prescribed or over-the-counter  medication.
●Vital signs, physical and neurological examination.
●Collect and review seizure diary kept since Visit [ADDRESS_63953], and/or 
parent/guardian as applicable.
●Explanation of potential adverse events will be reviewed, as will the reporting of adverse events.
●Blood work: CBC and C-reactive protein (CRP). If not done prior to visit as part of PST (pre 
surgical testing)
●Review of the specific protocol for medication administration. (Active Patients Only at NYU  CEC)
oThey  will be  instructed  on the dosage and administration times of the study medication. 
All subjects  will receive a specific quantity of tablets and they will be asked to record the 
time that each dose is given. They will be asked to bring back the medication that  was 
not used so it can be reconciled with expected number of tablets to be used. This 
reconciliation will be logged on the drug reconciliation form, and signed and dated by [CONTACT_58860]
6.2a  Visit 2a – For patients taking the Everolimus for [ADDRESS_63954] 7 days prior to Visit 3. For these patients with a combined Visit 1 and 2, this could 
mean a treatment  window of 7-21 days depending both on which  cohort they are in and how soon they 
can begin treatment.
Pre-surgical evaluation:  Visit 2- Control Group
●Recent  history will be reviewed for any change in medical status or change in intake of prescribed 
or over-the-counter medication.
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 26
●Vital signs, physical and neurological examination
●A detailed seizure history during the prior week.
●Medication reconciliation.
Blood work: (pre surgical eval) CBC and C-reactive protein (CRP).
For control patients  who reside outside of the NYC  area and are unable to arrive at the study site due to 
distance and travel issues prior to pre-admission  testing, Visits  1 and 2 will be combined as one visit and 
can be completed one day prior to Visit 3 if not earlier.
5.9 Visit 3 (Active/Control patients)– Day of Surgery NYU CEC
The
 following activities  will  be conducted and research subject  information  will be collected:
Study drug dosing: (ACTIVE PATIENTS ONLY)
●On the day of surgery, the patient will take their last dose of everolimus with a [ADDRESS_63955] 3 hours before surgery
●A detailed  seizure history during the prior week. A blood sample will be used for investigation per 
the IRB-approved protocol. This will include everolimus serum levels, systemic cytokines and 
mTOR activity levels. These samples will be batched and stored in -80 freezer until requested for 
analysis. )
During surgery:  (NYU Tisch Hospi[INVESTIGATOR_307])
●Intraoperative electrocorticography, performed in accordance with a standard protocol (see below).
●Resected tissue will be processed  by [CONTACT_58861] a 
sample will be used for investigation per the IRB-approved protocol. This tissue will be used for 
primary analysis of biochemical, molecular, electrophysiological, and genetic measures.
Corticography Protocol:
Equipment Needed:
1.Nicolet EEG Portable Acquisition unit
2.C64 Amplifier
3.2 x sterile Grass monopolar needle electrodes (1 – ground, 1 – reference)
4.[ADDRESS_63956] (8x8) Ad-tech electrode; spacing as follows:
a.If lesion is <=2 cm in maximal dimension, use grid with 5mm spacing
b.If lesion is 2.1-3 cm in maximal dimension, use grid with 7.5mm spacing
c.If lesion >3cm in maximal dimension, use grid with 10mm spacing
Anesthesia:
Remifentanil/propofol. If using  volatile  anesthesia,  turn off 15 minutes  prior to beginning 
recording.
Procedure:
1.Wheel portable EEG station into room, turn on and enter patient demographics as per routine
2.Configure 64-electrode montage in NicOne
3.Neurosurgeon to place ground and reference electrodes in scalp muscle adjacent to craniotomy
4.Neurosurgeon to photograph lesion
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page [ADDRESS_63957] ECoG for a minimum duration of 10 minutes using the following settings: High Pass  Filter  
1 Hz, Low Pass Filter 70 Hz, Gain 70uV/mm, notch filter off.
8.Neurosurgeon to place paper markers on [ADDRESS_63958]
5.10 Visit 4 (and all days with invasive electrodes) NYU Tisch  Hospi[INVESTIGATOR_58800], and every day thereafter  if invasive electrodes are utilized:
●The research subject will be seen by a board-certified neurosurgeon or study designee and 
evaluated for evidence of infection  and abnormal  wound healing as per the protocol (including 
digital photographs of the surgical site dressing) in both treated and untreated comparison 
groups.
oWe will  take photographs of the surgical  site dressing and subject’s face will not be in the 
photo. All photos will be de-identified in the same manner all of their clinical information 
for this study will be de-identified. Consent for the photographs are part of the consent 
form. The photographs will not be shared with anyone outside of the research team or 
anyone who is not a part of the patient’s medical  care.
●A board-certified neurologist/epi[INVESTIGATOR_58801].
– All seizures  and subclinical electrographic seizure discharges will be reviewed and the type 
(e.g., simple v. complex partial v. subclinical electrographic discharge), onset  region(s), 
spread zone(s), and duration.
– Each  day a standard  portion of the awake and sleep  EEG records and all seizures,  including 
the period for one minute before seizure onset and [ADDRESS_63959]/epi[INVESTIGATOR_58802]  a physical and 
neurological examination and inquire  about potential adverse events.
5.11 Visit 5a  (Active and concurrent comparison group) (if a second surgery is done at the 
end of invasive recordings) NYU Tisch  Hospi[INVESTIGATOR_58803]-approved protocol. This tissue will be 
used for research  analysis of biochemical,  molecular,  electrophysiological, and genetic measures.
6.5a Resected brain tissue will be distributed at the Pathology Department of the NYU  Medical 
Center then stored in the Alexandria Center for Life Sciences, located at [ADDRESS_63960]. Snuderl) will perform analysis of brain resection 
specimens from patients on this study, and will be used for preparation of DNA/RNA assays.  They will be 
looking for mutations in  mTOR pathway genes. The samples will be studied using next gen sequencing, 
proteomics and/or Micro RNA assays, to  search for mutations which may have caused the tuber or 
cortical dysplasia (CD). This analysis will focus on genes known to be involved in tuber/CD  development 
including TSC1, TSC2,  AKT1, AKT2, AKT3, MTOR, PTEN. Any variants that are found will be compared 
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page [ADDRESS_63961] in 
learning of the genetic findings, the findings will  be provided to them. This information will be offered to 
the patients and their families through a physician  or genetics counselor experienced with tuberous 
sclerosis. As this is not a clinical grade  (CLIA-certified) analysis, the findings will be presented as 
research findings, which must be confirmed by a CLIA lab if  any clinical action were considered based 
upon the information.  The results of the genetic analysis will not be shared with anyone outside of the 
research team. The use of samples for this study is required.
Our [ADDRESS_63962] activation using immunochemistry, 
western
 blotting analysis, and capture ELISA and other biochemical and molecular biology techniques o], 
in order to  obtain such results. He will be looking at levels of mTOR signaling proteins in lymphocytes of 
human blood  specimens. 2 mls in purple cap EDTA tube will suffice. For all Biochemical  assays we will 
utilize fresh frozen  tissue, For Immunohistochemistry fixed  frozen tissue  in 4% PFA and sucrose sank 
48hrs and frozen  using OCT blocks can be used. The panel of Abs used for detection will be a panel of 
set-fixed [ADDRESS_63963] – resection  
pathological TSC, or / and Epi[INVESTIGATOR_58804], and collected under an Approved ICF and under the 
supervision of the BRC  of NYULMC (in order to distribute), 
If subjects  wish to withdraw  from this portion of the study,  they will need to write a formal letter  to the 
Principal Investigator [INVESTIGATOR_58805], having  
their sample destroyed. The withdrawal procedures will be explained to them when they are signing  the 
consent form.
5.12 Visit 5b  Active and concurrent comparison group) (postoperative day 2 and all days 
until discharge) NYU Tisch Hospi[INVESTIGATOR_58806], they will
●Be seen by a board-certified neurosurgeon  or study designee and evaluated  for evidence of 
infection and abnormal  wound healing  as per the protocol (including  digital  photographs of the 
surgical site dressing).
●Be seen by a board-certified neurologist/epi[INVESTIGATOR_58807].
C O N F ID E N T IA L
T hi s d o c u m e n t a n d i nf or m ati on is  t he pr o p ert y o f t he N Y U  S c h o ol o f M e di ci n e  a nd L a n g o n e  M e di c al  C e nt er.  Do  n ot di s cl o se  or u s e 
e x c e p t as a ut h ori z e d  in writi n g b y t he  st u d y I ND s p o n s orE v er oli m u s  eff e ct s  on br ai n  m T O R  a nd e x cit a bilit y
V er si o n :  0 9/ 2 0/ 1 8P a g e 2 9
5. 1 3 Vi sit  6 ( A cti v e a n d c o n c urr e nt c o m p ari s o n gr o u p) N Y U C E C
[ADDRESS_63964] will:
●B e  e x a mi n e d  b y  a  b o ar d- c ertifi e d  n e ur o s ur g e o n  or  st u d y  d e si g n e e  a n d  e v al u at e d  f or e vi d e n c e  of  
i nf e cti o n a n d  a b n or m al  w o u n d  h e ali n g  a s  p er  t h e pr ot o c ol  (i n cl u di n g di git al  p h ot o gr a p h s  of  t h e 
s ur gi c al sit e  dr e s si n g).
●B e  e x a mi n e d  b y  a  b o ar d- c ertifi e d  n e ur ol o gi st/ e pil e pt ol o gi st  or  st u d y  d e si g n e e  t o r e vi e w c urr e nt 
m e di c ati o n s, a n y a d v er s e e v e nt s, a n d p erf or m a p h y si c al a n d n e ur ol o gi c al  e x a mi n ati o n.
[ADDRESS_63965] ati sti c s  ( m e a n s, m e di a n s,  i nt er q u artil e r a n g e s, st a n d ar d  d e vi ati o n s,  et c)  will  b e  pr o vi d e d  al o n g  
wit h  gr a p hi c al  di s pl a y s  ( e. g., b o x pl ot s)  b y  tr e at m e nt gr o u p.
S af et y  will  b e  s u m m ari z e d  wit hi n  a n d  a cr o s s  d o s e  d ur ati o n c o h ort s  a n d  c o m p ar e d  wit h  t h e e v e nt s  i n t h e 
c o m p ari s o n  gr o u p.
S [ADDRESS_63966] s  ( wit h 
a p pr o pri at e  tr a n sf or m ati o n s of  l e v el s if r e q uir e d t o m e et  t h e a s s u m pti o n s  of  t h e m et h o d.
Si mil ar  a n al y s e s  will  b e  c arri e d  o ut  f or all  a d diti o n al  c o nti n u o u s  e n d p oi nt s  of  i nt er e st. N o  a dj u st m e nt s  f or 
m ulti pli cit y will b e m a d e i n t hi s s m all st u d y. Bi v ari at e s c att er pl ot s a n d c orr el ati o n c o effi ci e nt s will al s o  b e  
pr o vi d e d  t o e x a mi n e  t h e a s s o ci ati o n s  b et w e e n  t h e m ulti pl e  e n d p oi nt s.
7. [ADDRESS_63967]  P o p ul ati o n( s) f or A n al y si s
All  p ati e nt s  w h o  r e c ei v e o n e  or  m or e  d o s e s  of  dr u g  will b e  i n cl u d e d i n t h e a n al y s e s  of  s af et y.  T h o s e  
p ati e nt s w h o u n d er g o s ur g er y will b e i n cl u d e d i n t h e a n al y s e s of S [ADDRESS_63968] s,  t h er e ar e  t w o c a s e s  of  w o u n d  h e ali n g  pr o bl e m s  or  t hr e e c a s e s 
of s eri o u s i nf e cti o n, i n cl u di n g w o u n d sit e i nf e cti o n. I n t h e c a s e of a w o u n d sit e i nf e cti o n, a n y  pr o bl e m s  
wit h  w o u n d  h e ali n g  will  b e  c o n si d er e d  s e c o n d ar y  t o t h e i nf e cti o n a n d N O T  a s  a  pri m ar y  w o u n d  h e ali n g  
pr o bl e m. T h e s e e sti m at e s ar e b a s e d o n n e ur o s ur gi c al e x p eri e n c e a n d r e p ort s wit h t h e fr e q u e n c y  of  
w o u n d h e ali n g pr o bl e m s of < 2 % a n d i nf e cti o n fr o m 1. 6 t o 8. 6 % i n si x p u bli s h e d s eri e s, wit h a  m e a n 
i nf e cti o n r at e of 5. 3 %.[ 3 3- 3 8]
F or  t h e a n al y si s  of  S [ADDRESS_63969]  a  diff er e n c e  of
│ 1. 4 │-  │ 1. 5  │ st a n d ar d  d e vi ati o n s b et w e e n t h e c o m p ari s o n c o ntr ol s a n d t h e tr e at e d gr o u p wit h [ADDRESS_63970] s  wit h  al p h a  = 0. 0 5  a n d  p o w er  of  8 0 %.  Pr eli mi n ar y  d at a  u si n g  q u a ntit ati v e  W e st er n  bl ot s  o bt ai n e d  
fr o m [ADDRESS_63971] e d t u b er s d e m o n str at e d  p h o s p h o- S 6/ S 6  r ati o s of  2 5 7  4 2 %  of  c o ntr ol.  Wit h  [ADDRESS_63972]  a  6 2  –  6 5 %  diff er e n c e  i n p h o s p h or- S 6/ S [ADDRESS_63973] u di e s  i n 
m uri n e m o d el s of T S C tr e at e d wit h r a p a m y ci n h a v e d e m o n str at e d 9 0 % r e d u cti o n i n p h o s p h o- S 6  l e v el s 
[r ef]
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page [ADDRESS_63974] or other means, will be collected 
and recorded and followed as appropriate.
6.2 Adverse  events
6.2.1 Definitions and reporting
Adverse events that  begin  or worsen after informed  consent  should be recorded  in the Adverse Events 
CRF. Conditions that were already  present at the time of informed consent  should  be recorded in the 
Medical History page of the patient’s CRF. Adverse event monitoring should be continued for at least  30 
days (or 5 half-lives, whichever is longer) following the last dose of study treatment. Adverse events  
(including lab abnormalities that constitute AEs) should be described using a diagnosis whenever 
possible, rather than individual underlying  signs and symptoms. When  a clear diagnosis cannot be 
identified, each sign or symptom should be reported as a separate Adverse Event.
The occurrence of adverse  events  should be sought by [CONTACT_105]-directive questioning of the patient at each 
visit during the study. Adverse events also may be detected when they are volunteered by [CONTACT_58862], laboratory test, or other assessments. As far as 
possible, each adverse event should be evaluated to determine:
1.The severity grade (CTAE Grade 1-4)
2.Its duration (Start and end dates or if continuing at the Safety Follow-up Visit)
3.Its relationship to the study treatment (Reasonable possibility that AE is related: No,  Yes)
4.Action  taken with respect  to study or investigational treatment (none,  dose adjusted, temporarily  
interrupted, permanently discontinued, hospi[INVESTIGATOR_057], unknown, not applicable)
5.Whether medication or therapy was given (no concomitant medication/non-drug therapy, concomitant 
medication/non-drug therapy)
6.Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, recovered/resolved 
with sequalae, fatal, unknown)
7.Whether it is serious, where a serious adverse event (SAE) is defined as in Section  8.2.1
All adverse  events should  be treated  appropriately.  Such  treatment may include changes  in study drug 
treatment including possible interruption or discontinuation, starting or stoppi[INVESTIGATOR_58808], 
changes in the frequency or nature of assessments,  hospi[INVESTIGATOR_059], or any other medically  required 
intervention. Once an adverse event is detected, it should be followed until its resolution, and assessment 
should be made at each visit (or more frequently, if necessary) of any changes in severity, the suspected 
relationship to the study drug, the interventions  required to treat it, and the outcome.
Information about common side effects already known about the investigational drug can be found in the 
[Investigators’ Brochure]. This information should be included in the patient informed consent and should 
be discussed with the patient during the study as needed.
Adverse event  monitoring  should be  continued for at least [ADDRESS_63975] abnormalities
Laboratory
 abnormalities that  constitute  an Adverse Event in their own right (are considered clinically 
significant, induce clinical  signs or symptoms, require concomitant therapy or require changes in study 
treatment), should be recorded on the Adverse Events CRF. Whenever possible, a diagnosis, rather than 
a symptom should be provided (e.g. anemia instead  of low hemoglobin). Laboratory  abnormalities  that 
meet the criteria for Adverse Events should be followed until they have returned to normal or an adequate 
explanation of the abnormality is found.  When an abnormal laboratory or test result corresponds to a
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 30
sign/symptom of an  already  reported adverse event, it is not necessary to separately record the lab/test 
result as an additional event.
Laboratory abnormalities, that do not meet the definition of an adverse event, should not be reported as 
adverse events.  A Grade 3 or 4 event (severe) as per CTAE does not automatically indicate a SAE 
unless it meets the definition  of serious as defined below and/or as per investigator’s discretion.  A dose 
hold or medication for the lab abnormality  may be required by [CONTACT_107], by [CONTACT_108],  an 
adverse event.
6.2.[ADDRESS_63976] (optional)
In clinical trials, everolimus has been associated with serious cases of hepatitis B reactivation, including  
fatal outcome.  Reactivation of infections is an expected  event during periods of immunosuppression.
In clinical trials  and post-marketing spontaneous  reports, everolimus has been associated  with renal 
failure events (including  fatal ones) and proteinuria.  Renal  function  will be monitored  throughout  the 
study. In clinical trials everolimus has been associated with certain  adverse  events  (Table 6).
Table 6. Specific Adverse  Events
Clinically Notable AE  
groupi[INVESTIGATOR_58809] (RMP) Comment
Amenorrhea Amenorrhea Included under potential risk in RMP
Cytopenia N/A Included under clinically notable  AEs
Hemorrhages Hemorrhages Included as important identified risk in the RMP
Hyperglycemia/ new 
onset 
of diabetes  
mellitusN/A
Included under clinically notable  AEs
Hypersensitivity 
reactions 
(anaphylactic
 reaction)N/A
Included under clinically notable  AEs
Infections and 
infestationsN/A
Included under clinically notable  AEs
Intestinal 
obstruction/ileusIntestinal 
obstruction/ileusIncluded under potential risk
N/A Cardiac Failure Not reported in the MAP. (important identified risk- RMP 
specific
N/AIncreased 
creatininePlease note that this RMP specific identified risk is based 
on lab data and is defined as newly occurring or 
worsening increase to CTC grade 3 or 4
Non infectious 
pneumonitisNon infectious 
pneumonitisName [CONTACT_58875]. Included under important 
identified risk in RMP
Rash and similar 
eventsN/A
Not included in the RMP
Renal events Renal 
failure/proteinuri
aThe names in RMP and MAP are different but the search 
terms are the same. It is included important identified risk 
in RMP
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 31
Stomatitis/oral 
mucositis/ulcersN/A
Included under clinically notable  AEs
Thromboembolism Thromboembolism Included as important identified risk in the RMP
6.3 Serious Adverse Events
6.3.1 Definitions
A serious adverse event is an undesirable sign, symptom or medical condition which:
●is fatal or life-threatening
●results in persistent or significant disability/incapacity
●constitutes a congenital anomaly/birth defect
●requires  inpatient hospi[INVESTIGATOR_29350], unless hospi[INVESTIGATOR_58810]:
●routine  treatment or monitoring of the studied indication, not associated  with any deterioration in 
condition (specify what this includes)
●elective  or pre-planned treatment for a pre-existing condition that is unrelated to the indication  under 
study and has not worsened since the start of study drug
●treatment  on an emergency outpatient basis for an event not fulfilling any of the definitions  of a SAE 
given above and not resulting in hospi[INVESTIGATOR_063]
●social reasons and respi[INVESTIGATOR_064]’s general condition
●is medically significant,  i.e., defined as an event that jeopardizes the patient  or may require medical or 
surgical intervention to prevent one of the outcomes listed  above
6.3.2 Reporting
The principal investigator  [INVESTIGATOR_58811], IRB, and 
[COMPANY_001] Pharmaceuticals Drug Safety and Epi[INVESTIGATOR_18540] (DS&E).
All events reported to the FDA by [CONTACT_109]  3500A  
(MedWatch Form).
To ensure patient safety, every SAE, regardless of suspected causality, occurring
●after the patient has provided informed consent and until atl east 30 days after the patient has 
stopped study treatment/participation
●after protocol-specified procedures begin and 30 days after the patient has stopped study treatment
●after the start of any period in which the study protocol  interferes  with the standard  medical  treatment 
given to a patient  (e.g., treatment withdrawal during  washout period, change  in treatment to a fixed  
dose of concomitant medication) and until [ADDRESS_63977] be reported  to [COMPANY_001] within 24 hours of learning of its occurrence  (fax: [PHONE_002]).  This 
includes serious, related, labeled (expected) and serious, related, unlabeled (unexpected)  adverse 
experiences. All deaths during treatment or within [ADDRESS_63978] be kept within the Trial Master 
File at the study site.
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 32
Follow-up information is sent to the same fax number as the original SAE Report Form was sent, using a 
new fax cover sheet, stating that this is a follow-up to the previously reported SAE, and giving the date of 
the original  report. Each re-occurrence, complication, or progression  of the original event should be 
reported as a follow-up  to that event  regardless of when it occurs.  The follow-up  information should 
describe whether the event has resolved or continues, if and how it was treated, and whether the patient  
continued or withdrew from study participation.
If the SAE is not previously documented in the Everolimus Investigator Brochure or Package Insert  (new 
occurrence)
 and is thought  to be related to the [COMPANY_001] study drug, a DS&E associate may urgently 
require further information from the investigator for Health Authority reporting. [COMPANY_001] may need to issue 
an Investigator Notification  (IN), to inform all investigators involved in any study with the same drug that 
this SAE has been reported. Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be 
collected and reported to the competent authorities and relevant ethics committees in accordance with 
Directive 2001/20/EC or as per national regulatory  requirements in participating countries.
6.3.3 Investigator reporting: notifying the NYULMC  IRB
This section describes the requirements for safety reporting by [CONTACT_58863], 
affiliated with a NYULMC  research site, or otherwise responsible for safety reporting to the NYULMC IRB. 
The NYU Langone Medical Center IRB (NYULMC IRB) requires expedited reporting of those events 
related to study participation  that are unforeseen  and indicate that participants or others are at increased 
risk of harm. The NYULMC IRB will not acknowledge safety reports or bulk adverse event  submissions 
that do not meet the criteria outlined below. The NYULMC IRB requires researchers to submit reports of 
the following problems  within 5 working  days from the time the investigator becomes aware of the event:
A reportable event  is an event that occurs at any time during or after the research study, which in the 
opi[INVESTIGATOR_58812]:
●Unexpected: An event is “unexpected” when its specificity and severity are not accurately 
reflected in the protocol-related documents, such as the IRB-approved research protocol, any  
applicable investigator brochure, and the current IRB-approved informed consent document  and 
other relevant sources of information, such as product labeling and package inserts.
AND
●Related to the research procedures: An event is “related to the research procedures” if in the 
opi[INVESTIGATOR_58813],  the event was more likely than not to be caused 
by [CONTACT_58864].
AND
●Harmful: Harmful includes causing harm to participants or others, or placing them at increased 
risk of  harm.
Reporting
 Process
Unanticipated problems posing risks to subjects or others as noted above will be reported to  the   
NYULMC IRB or St Barnabas Medical  Center IRB using  the form:  “Reportable Event  Form” or as a written 
report of the event (including a description of the event with information regarding its fulfillment of the 
above criteria, follow-up/resolution and need for revision to consent form and/or other study 
documentation).
Copi[INVESTIGATOR_58814]’s study file.
Other Reportable events:
For
 clinical  drug trials,  the  following events are also reportable to the NYULMCIRB:
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 33
●Any adverse experience that, even without detailed  analysis, represents a serious unexpected  
adverse event  that is rare in the absence of drug exposure  (such as agranulocytosis,  hepatic  
necrosis, Stevens-Johnson syndrome).
●Any adverse event that would cause the sponsor to modify the investigators brochure, protocol or 
informed consent form, or would  prompt other action by [CONTACT_58865].
●Information  that indicates a change  to the risks or potential benefits of the research, in terms of 
severity or frequency. For example:
– An interim  analysis indicates that participants have a lower  rate of response to treatment than 
initially expected.
– Safety monitoring  indicates that a particular side effect is more severe, or more frequent than 
initially expected.
– A paper  is  published  from another study  that shows that an arm of your research  study is of no 
therapeutic value.
●Change in FDA safety labeling  or withdrawal from marketing of a drug, device, or biologic used in 
a research protocol.
●Breach of confidentiality
●Change to the protocol taken without prior IRB review to eliminate  apparent immediate hazard to a 
research participant.
●Incarceration of a participant when  the research was not previously approved  under Subpart C 
and the investigator  believes  it is in the best interest of the subject to remain on the study.
●Complaint of a participant when the complaint  indicates unexpected risks, or the complaint cannot 
be resolved by [CONTACT_5051].
●Protocol violation (meaning an accidental or unintentional deviation from the IRB approved 
protocol) that in the opi[INVESTIGATOR_58815], or 
affects the rights or welfare of subjects.
6.3.4 Investigator reporting: Notifying a non-NYULMC/ IRB
Not Applicable
6.3.5 Sponsor reporting: Notifying the FDA
The study IND  sponsor  is required to report certain study events in an expedited fashion to the FDA.  
These written notifications  of adverse events are referred to as IND safety reports. The following 
describes the safety reporting requirements by [CONTACT_28822]:
●Within 7 calendar days (via telephone or facsimile report)
Any study event that is:
– associated with the use of the study drug,
– unexpected,
– fatal or life-threatening
●Within 15 calendar days (via written report)
Any study event that is:
– associated with the use of the study drug,
– unexpected, and
–
serious, but not fatal or life-threatening
-or-
–
a previous  adverse  event that was not initially deemed reportable but is later found  to fit the 
criteria for reporting (reporting within 15 calendar days from when event was deemed 
reportable).
Any finding from  tests in laboratory animals  that:
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 34
– suggest a significant risk for human subjects including reports of mutagenicity,  teratogenicity, 
or carcinogenicity.
Additional reporting requirements
Sponsors 
are also required to identify in IND safety reports all previous reports concerning  similar 
adverse events and to analyze the significance of the current event  in light of the previous reports.
Reporting Process
Adverse events  may be submitted on FDA Form 3500A or in a narrative format. If supplied as in a 
narrative format,  the minimum information to be supplied  is noted  above at the beginning  of section 8.3. 
The contact [CONTACT_58866]:
6.3.6 Sponsor  reporting: Notifying participating investigators
Not Applicable
6.4 Unblinding  Procedures
Not
 applicable.
6.5 Stoppi[INVESTIGATOR_1869]
A 
Data Safety Monitoring Program (DSMP) will be established to monitor adverse events and study 
safety. 
Prior to commencement of the study, the rate of infection and impaired wound healing associated  
with routine two-stage epi[INVESTIGATOR_58816] 5 years will be 
determined for each epi[INVESTIGATOR_58817] (Amanda Yaun and Werner Doyle). A statistician from the NYU  
School of Medicine Biostatistics Department will provide blinded reports to the Data Safety Monitoring 
Committee (DSMC). The PI, [CONTACT_58877],Dr.Amanda Yaun, David Harter and [CONTACT_58878] (co- 
investigators) will aid in reviewing all patients during the treatment period and throughout the post-  
treatment monitoring period. They will review all cases and if it is deemed that the serious adverse 
event(s) are related to study drug, the study will be terminated for that subject. If two patients among  the 
9 treated with everolimus develop a) impaired  surgical  wound healing or if three patients among the 9 
develop b) serious infection, including wound site infection. Any case of wound site infection complicated 
by a wound  healing  problem  will NOT be considered  a wound healing problem.
Medical Monitoring
It is the responsibility of the Principal Investigator [INVESTIGATOR_58818]. This  safety 
monitoring
 will include  careful assessment and appropriate reporting  of adverse events as noted above,  
as well as the construction and implementation of a site data and safety-monitoring plan (see section 10. 
Auditing, Monitoring and Inspecting). Medical monitoring will include a regular assessment of the number 
and type of serious adverse  events..
It is the responsibility of the IND Sponsor to assess research subject safety.
Data 
Safety Monitoring Program (DSMP), Data Safety Monitoring Committee (DSMP): The investigators 
will review all safety data after each three subject treatment cohort has completed the trial. All safety  data 
will be sent to the DSMB after every [ADDRESS_63979] in prior research studies and now FDA approved for patients with TSC. However, all 
adverse events will be recorded and reviewed.
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page [ADDRESS_63980] member of the DSMP, including fatigue, rash, anorexia, mucositis, edema, cough, 
thromboembolism, nausea, vomiting, stomatitis, sinusitis, bronchitis, pneumonia,  abscess, leukopenia,  or 
hyperlipi[INVESTIGATOR_035].
Because of the specific concern regarding potential wound healing problems and wound  infection 
resulting from treatment  with everolimus  prior to elective epi[INVESTIGATOR_58819], wound status will be carefully 
monitored, specifically by a neurosurgeon.
The site of the  planned surgical  incision will be inspected by [CONTACT_58867] 5 days after 
initiating therapy (prior to surgery), and then at weekly intervals, beginning one week after surgery until 
six weeks after surgery. The neurosurgeon will document wound status with digital  photography.
Blood test surveillance  for possible infection will be performed at the same time intervals (7-[ADDRESS_63981]) consisting  of a complete  blood count (CBC) with differential and 
C-reactive protein (CRP).
Any abnormality will  be documented for review by [CONTACT_58868].  Since no ideal objective scoring system 
exists for assessing  surgical site adverse  events [39,40], any wound  breakdown, dehiscence or infection 
will be considered a serious adverse event, and will be reported to the participating site IRB and to the 
NINDS, and the decision  will be made as to whether the study should  be terminated.
Individual subject participation  in the study will be terminated if the DSMC  finds any of the following  
unexpected new findings in a subject:
1)Documented wound infection requiring surgery
2)Documented wound dehiscence requiring surgery
3)Persistent  fever above  101 degrees F and abnormally elevated serum wbc count and ESR and CRP in 
the absence of a known cause
4)Documented bacterial meningitis
6.6 Source Documents
Source
 data is  all information, original  records of clinical  findings, observations, or other activities in a 
clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in 
source documents. Examples of these original documents, and data records include: hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation  checklists, 
pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_19093], microfiches, photographic negatives, microfilm 
or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories, and at 
medico-technical departments involved in the clinical  trial.
6.7 Case Report Forms
The study case report form (CRF) is the primary data collection instrument for the study. All data  
requested on the CRF must be recorded in a digital RedCap database system. All missing data must  be 
explained. If a space on the CRF is left blank because the procedure was not done or the question  was 
not asked, write “N/D”.  If the item is not applicable to the individual case, write “N/A”.  All entries  should 
be printed legibly in black ink. If any entry error has been made, to correct such an error, draw a single 
straight line through the incorrect entry and enter the correct data above it. All such changes must be 
initialed and dated. DO NOT ERASE OR WHITE OUT ERRORS. For clarification of illegible or uncertain 
entries, print the clarification above the item, then initial and date it.
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page [ADDRESS_63982] locking at case report form (CRF)  and subject level and the paperless  query features  allow 
for the cleaning of data throughout the clinical study.  The system  has extensive security features and all 
data transmitted into or out of the REDCap  database will be encrypted.
Study Data Management  staff will conduct data management and data quality assurance work activities 
for the A Pi[INVESTIGATOR_58820] (TSC)  and Focal Cortical Dysplasia  (FCD) study. Data 
Management staff will be responsible  for the integrity of all study data. They will review and monitor the 
completeness and accuracy of data thought out the duration of the study. Final data clean up will be 
completed shortly  after the last subject visit and the study database will be locked and provided  to the 
study statistician for analyses.
A CRF will be completed for each subject. This CRF has proven successful in previous studies. It is the  
investigator’s responsibility to ensure the accuracy, completeness, clarity, and timelines of the data 
reported in the subject’s CRF. Source documentation supporting the CRF data should indicate the 
subject’s participation in the study and should document the dates and details of study  procedures, 
adverse events, other observations, and subject  status.
The investigator, or  designated  representative, should complete the CRF as soon as possible 
after information is collected. An explanation should be provided for all missing data.
The PI, [CONTACT_58879],  will provide  the study site with CRF training sufficient to permit  site personnel to 
enter or correct information  in the CRFs for the subjects for which they are responsible.
6.8.1 Data Collection Forms: To be submitted by [CONTACT_58869] 48 hours of registration completion: On-study CRF, Signed, Dated Consent, On-Study Lab 
Reports, Medical History CRF, Eligibility Checklist; Within two weeks of registration: Pre-Operative 
Evaluation CRF, Completed Subject Diaries, Complete Lab test results;  Within two weeks post surgery: 
Post-Op evaluation  CRF,  Off-Study  Evaluation CRF; Within two weeks post-surgery, within 30 days for all 
other AE’s: Toxicity CRFs; Within 24 hours of event occurrence: SAE’s Hospi[INVESTIGATOR_58821]/Discharge Summaries
6.8.[ADDRESS_63983] Identifiers
Each patient will  be given a unique  identifier  (study  number) in the order of enrollment. Each blood and 
tissue sample will be placed  in an individual cryotube labeled with study number, date of surgery,  and 
time of collection.
6.8.[ADDRESS_63984], be identified by a unique  identifier (study number).  This 
study number will also be used for research specimens collected and shipped to collaborating 
laboratories. Clinical  information will be accessed,  according to HIPAA requirements, by [CONTACT_58870],  as needed. Only the PI [INVESTIGATOR_58822], birth date,  and medical record number. The log will be 
kept in a secure file.
C O N F ID E N T IA L
T hi s d o c u m e n t a n d i nf or m ati on is  t he pr o p ert y o f t he N Y U  S c h o ol o f M e di ci n e  a nd L a n g o n e  M e di c al  C e nt er.  Do  n ot di s cl o se  or u s e 
e x c e p t as a ut h ori z e d  in writi n g b y t he  st u d y I ND s p o n s orE v er oli m u s  eff e ct s  on br ai n  m T O R  a nd e x cit a bilit y
V er si o n :  0 9/ 2 0/ [ADDRESS_63985]’ s m e di c al r e c or d i s  al s o  
pr ot e ct e d b y f e d er al pri v a c y  r e g ul ati o n s.
S u bj e ct s  will  b e  i nf or m e d of  all  pr ot e ct e d  h e alt h  i nf or m ati o n u s e d  i n t hi s st u d y.  T h e  c o n s e nt  f or m will  s e e k 
writt e n  p er mi s si o n  fr o m t h e p ati e nt  t o u s e  a n d  di s cl o s e  i nf or m ati o n f or t hi s r e s e ar c h. T h e  p ati e nt  or  p ar e nt  
i s r e q uir e d t o si g n  t hi s f or m. T hi s  A ut h ori z ati o n  will  n ot  e x pir e  u nl e s s  t h e p ati e nt  wit h dr a w s  it i n writi n g.
T h e  v ol u nt e er  h a s  t h e ri g ht t o wit h dr a w  a ut h ori z ati o n  at  a n y  ti m e, e x c e pt  t o t h e e xt e nt  t h at N Y U  h a s  
alr e a d y  r eli e d u p o n  it or  m u st  c o nti n u e  t o u s e  t h e i nf or m ati o n t o c o m pl et e  d at a  a n al y si s  or  t o r e p ort d at a  
f or t hi s st u d y.
6. 8. [ADDRESS_63986] e d c o m p ut er. Writt e n a n d el e ctr o ni c r e c or d s, 
r e p ort s, a n d d at a r e s ulti n g fr o m t hi s cli ni c al tri al will b e k e pt i n t h e v ol u nt e er’ s r e s e ar c h r e c or d f or at l e a st 
si x  y e ar s  or  u ntil  t h e st u d y  i s c o m pl et e d,  w hi c h e v er  i s l o n g er. At  t h at ti m e, eit h er  t h e r e s e ar c h i nf or m ati o n 
n ot  alr e a d y  i n t h e m e di c al  r e c or d will  b e  d e str o y e d  or  i nf or m ati o n i d e ntif yi n g t h e p ati e nt  will  b e  r e m o v e d 
fr o m s u c h  st u d y  r e s ult s at  N Y U.  A n y  r e s e ar c h i nf or m ati o n i n t h e m e di c al  r e c or d will  b e  k e pt  i n d efi nit el y.
6. 8. [ADDRESS_63987] s.
6. 9 R e c or d s  R et e nti o n
It i s t h e i n v e sti g at or’ s r e s p o n si bilit y t o r et ai n st u d y  e s s e nti al  d o c u m e nt s  f or at  l e a st [ADDRESS_63988] a n
T h e  Pri n ci p al  I n v e sti g at or ( [CONTACT_58880] n  D e vi n s k y)  will  f oll o w t h e d at a  s af et y  m o nit ori n g  pl a n  b el o w  t o e n s ur e  
t h at all s af et y m e a s ur e s ar e t a ki n g pl a c e i n t h e b e st i nt er e st of t h e s u bj e ct s.
D at a S af et y  M o nit ori n g Pl a n ( D S M P)
W h o will  d o t h e d at a m o nit ori n g f or t hi s st u d y:
●T h e PI, Orri n D e vi n s k y,  M D.
●T h e s u b i n v e sti g at or, A m a n d a Y a u n,  M D
●T h e i n d e p e n d e nt m o nit or, Di mitri o Ar kil o a s,  M D
E x pl ai n h o w d at a  s af et y will b e m o nit or e d:
●Dr u g  t ol er a bilit y a n d  s af et y  will  b e  m o nit or e d  d uri n g  cli ni c al  e v al u ati o n s  a n d  p h o n e  vi sit s  b y  
i n v e sti g at or/ st u d y t e a m m e m b er t h at will s e e k i nf or m ati o n o n a d v er s e e v e nt s b y s p e cifi c 
q u e sti o ni n g a n d, a s a p pr o pri at e, b y  e x a mi n ati o n.
.
●Dr.  D e vi n s k y,  Dr.  Y a u n  a n d  Dr.  D o yl e  will  r e vi e w all  p ati e nt s  d uri n g  t h e tr e at m e nt p eri o d  a n d  
t hr o u g h o ut t h e p o st-tr e at m e nt p eri o d.  T h e y will r e vi e w all c a s e s a n d if it i s d e e m e d t h at t h e 
s eri o u s  a d v er s e  e v e nt( s)  ar e  r el at e d t o st u d y  dr u g,  t h e st u d y will  b e  t er mi n at e d f or t h at s u bj e ct.  If  
t w o p ati e nt s  a m o n g  t h e 9  tr e at e d wit h  e v er oli m u s  d e v el o p  a)  i m p air e d s ur gi c al  w o u n d  h e ali n g  or  if 
t hr e e p ati e nt s a m o n g t h e 9 d e v el o p b) s eri o u s i nf e cti o n, i n cl u di n g w o u n d sit e i nf e cti o n, st u d y 
t er mi n ati o n will o c c ur. A n y c a s e of w o u n d sit e i nf e cti o n c o m pli c at e d b y a w o u n d h e ali n g, t h e 
pr o bl e m will N O T b e c o n si d er e d a w o u n d h e ali n g pr o bl e m, b ut s e c o n d ar y t o t h e  i nf e cti o n.
C O N F ID E N T IA L
T hi s d o c u m e n t a n d i nf or m ati on is  t he pr o p ert y o f t he N Y U  S c h o ol o f M e di ci n e  a nd L a n g o n e  M e di c al  C e nt er.  Do  n ot di s cl o se  or u s e 
e x c e p t as a ut h ori z e d  in writi n g b y t he  st u d y I ND s p o n s orE v er oli m u s  eff e ct s  on br ai n  m T O R  a nd e x cit a bilit y
V er si o n :  0 9/ 2 0/ 1 8P a g e 3 8
●T h er e i s a ri s k of P HI di s s e mi n ati o n. All p er s o n al h e alt h i nf or m ati o n ( o n p a p er) will b e st or e d  at  
N Y U C o m pr e h e n si v e E pil e p s y C e nt er l o c at e d at [ADDRESS_63989]  m a y  h a v e:
N o n e.
D at a S af et y  M o nit or D et ail s:
T h e e nr oll e d s u bj e ct s  will b e m o nit or e d:
Dr u g
●P ati e nt s will b e r o uti n el y m o nit or e d f or a d v er s e e v e nt s vi a cli ni c al e v al u ati o n s a n d p h o n e  vi sit s
●S u bj e ct s will h a v e t h e r e s e ar c h c o or di n at or’ s p h o n e n u m b er t o c all i n c a s e of n e e d t o r e p ort  si d e 
eff e ct s o n d a y s n ot s c h e d ul e d f or cli ni c al e v al u ati o n or p h o n e  vi sit.
P HI
●All P HI will b e k e pt i n l o c k e d fili n g c a bi n et at N Y U C o m pr e h e n si v e E pil e p s y C e nt er  a n d/ or  
e nt er e d i nt o R E D C a p ( N Y U s e c ur e d at a m a n a g e m e nt s y st e m) wit h a c c e s s gi v e n o nl y t o  st u d y 
p er s o n n el
Dr o p o ut s will  b e m o nit or e d:
●Dr o p o ut s  will  h a v e  a  fi n al vi sit  t o c o m pl et e  t h eir e nr oll m e nt  a n d  r e c ei v e i n str u cti o n s f or t a p eri n g 
off of  E v er oli m u s.
.
Pri m ar y a n d  s e c o n d ar y effi c a c y e n d p oi nt s will b e  m o nit or e d:
T h e  pri m ar y  st u d y  e n d p oi nt s  of  t h e s af et y  a n d  t ol er a bilit y of  e v er oli m u si n  c hil dr e n  a n d  y o u n g  a d ult s  a n d  
t h e e st a bli s h m e nt of o pti m al d o s e will b e m o nit or e d vi a:
●Si d e Eff e ct s i n c hil dr e n a n d s u bj e ct s w h er e c ar e gi v er r e p ort s a n d i n a d ult s t h at ar e a bl e t o  s elf 
r e p ort.
●E v al u ati o n of s ei z ur e di ar y at cli ni c al e v al u ati o n s a n d p h o n e  vi sit s
T h e  s e c o n d ar y  st u d y  e n d p oi nt  of  c h a n g e  i n fr e q u e n c y fr o m b a s eli n e  will  b e  m o nit or e d  vi a:
●E v al u ati o n of s ei z ur e di ar y at cli ni c al e v al u ati o n s a n d p h o n e  vi sit s
R e p ort a bl e e v e nt s  will b e m o nit or e d u si n g a n a c c e pt e d s c al e:
N o,  t h er e will  b e  n o  a c c e pt e d  s c al e  f or m o nit ori n g  r e p ort a bl e e v e nt s.  All  r e p ort a bl e e v e nt s  will  b e  f oll o w e d 
u ntil  r e s ol uti o n, st a bili z ati o n,  or  u ntil  it h a s  b e e n  d et er mi n e d  t h at t h e st u d y  tr e at m e nt or  p arti ci p ati o n  i s n ot  
t h e c a u s e. If t h e r e p ort a bl e e v e nt i s still o n g oi n g at t h e e n d of t h e st u d y, it will b e f oll o w e d u ntil fi n al 
o ut c o m e h a s b e e n  r e a c h e d.
D e s cri b e t h e  fr e q u e n c y of m o nit ori n g:
T h e  I n d e p e n d e nt m o nit or  will  e v al u at e  e v er y  [ADDRESS_63990] a c e:
N o,  i nt eri m a n al y si s  will  n ot  t a k e pl a c e  u nl e s s  r e q u e st e d b y  t h e I R B.
R e p ort a bl e  e v e nt s
T hi s  pr ot o c ol  will  a d h er e  t o N Y U  S O M  I R B p oli c y  f or r e p ort a bl e e v e nt s  r e p orti n g: Y e s,  w e  will  a d h er e  t o 
t h e p oli c y  f or r e p ort a bl e e v e nt s.  W e  will  al s o  b e  r e p orti n g t o N o v arti s  P h ar m a c e uti c al s  C or p or ati o n.
D e s cri pti o n of  D at a S af et y M o nit ori n g
[ADDRESS_63991] u g or w h o s e P HI w a s a c ci d e nt all y  di s s e mi n at e d.
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page [ADDRESS_63992]. Arkiloas (the independent monitor) will be responsible for evaluating and 
monitoring data.  They will oversee the DSMP and DSMR.
3.Information about the monitoring entity
The independent monitor,  [CONTACT_58881], is the monitoring entity.
4.Reportable  events that will be reported to the monitoring entity and when the events  will be reported 
Yes, all reportable events will be immediately reported to the PI [INVESTIGATOR_58823],  study 
personnel, co-investigators or anyone who is aware of a reportable event. Reportable  events  may be 
reported by [CONTACT_58871].
5.Assessment for the frequency of monitoring
We will submit a Data Safety Monitoring Report every [ADDRESS_63993] is identified and 
considered as a possible or definite result of the study medication. These include rash, other signs of 
hypersensitivity, or liver function tests that exceed baseline or normal measures by 50%. Clinical 
judgment will be used when determining need for everolimus therapy to be terminated. Other reasons  for 
withdrawal include non-compliance with study procedures, seizure exacerbation, or interaction with 
current concomitant AED therapy. The method termination of everolimus therapy will be determined 
based on type of reaction and/or reason for withdrawal.
7.Communication and dissemination of information
If any accidental  dissemination of PHI occurs, the independent monitor, [CONTACT_58882],  will communicate 
with the IRB  immediately.
7.2 Auditing  and Inspecting
The Investigator will permit study-related monitoring, audits, and inspections by [CONTACT_1201], government  
funding and regulatory bodies, and NYULMC compliance and quality assurance groups of all study 
related documents  (e.g. source documents, regulatory documents, data collection instruments,  study data 
etc.). The investigator will ensure the capability for inspections of applicable study-related facilities (e.g. 
pharmacy, diagnostic laboratory,  etc.).
Participation as an  investigator in this study implies acceptance of potential  inspection by [CONTACT_58872].
8 Ethical Considerations
This
 study is  to be conducted accordance with applicable: US government regulations, international 
standards of Good Clinical Practice, and institutional research policies and procedures.
This protocol  and any  amendments  will be submitted  to a properly constituted  Institutional Review Board 
(IRB) in agreement with local legal prescriptions, for formal approval of the study conduct.  The decision  
of the IRB concerning the conduct of the study will be made in writing to the investigator and a copy of this 
decision will be provided to the sponsor before commencement of this study. The investigator should 
provide a list of IRB members and their affiliate to the  sponsor.
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 40
All subjects for  this study will be provided  a consent  form describing this study and providing  sufficient 
information for subjects to make an informed decision about their participation in this study. Assent  will 
not be required since all of the children in this study will be cognitively impaired. All consent will be 
coming from their legal guardians/parents/health care proxy. A consent form will be submitted with the 
protocol for review and approval by [CONTACT_14884]. The formal consent of a subject, using the 
IRB/EC-approved consent  form, must be obtained before  that subject undergoes  any study procedure.  
The consent form must  be signed by [CONTACT_58873],  and the investigator- 
designated research professional obtaining the consent.
[ADDRESS_63994] with this study (patent ownership, royalties, or financial gain 
greater than the minimum allowable by [CONTACT_1385], etc.) must report this to the study IND  Sponsor  
and have the conflict reviewed by a properly constituted  Conflict of Interest Committee with a Committee-  
sanctioned conflict management plan that has been reviewed and approved by [CONTACT_21805]. All NYULMCinvestigators will follow the applicable University conflict of  interest 
policies.
9.[ADDRESS_63995] party without the consent of the study sponsor.
12 References
1. Madhavan, D., et al., Surgical outcome in tuberous sclerosis complex: a multicenter  survey. 
Epi[INVESTIGATOR_8330], 2007. 48(8): p. 1625-8.
2. Numis, A.L., et al., Identification of risk factors  for autism  spectrum  disorders  in tuberous  sclerosis 
complex. Neurology, 2011. 76(11): p. 981-7.
3. van Eeghen, A.M., et al., Cognitive  and adaptive development of patients  with tuberous sclerosis 
complex: a retrospective, longitudinal investigation. Epi[INVESTIGATOR_002] & behavior : E&B,  2012. 23(1):  p. 
10-5.
4. Devinsky, O., Sudden, unexpected death in epi[INVESTIGATOR_002]. The New England journal  of medicine, 
2011. 365(19): p. 1801-11.
5. Meikle, L., et al., Response of a neuronal  model  of tuberous sclerosis to mammalian target  of 
rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival 
and function. J Neurosci, 2008. 28(21): p. 5422-32.
6. Zeng, L.H., et al., Rapamycin prevents epi[INVESTIGATOR_58824] a mouse model of tuberous sclerosis complex. 
Ann Neurol, 2008. 63(4): p. 444-53.
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 41
7. Goto, J., et al., Regulable neural progenitor-specific Tsc1  loss yields giant cells with organellar  
dysfunction in a model of tuberous  sclerosis  complex. Proceedings of the National Academy of 
Sciences of the [LOCATION_002] of America, 2011. 108(45): p. E1070-9.
8. Krueger,  D.A., et al., Everolimus for subependymal giant-cell  astrocytomas in tuberous  sclerosis. 
N Engl J Med, 2010. 363(19): p. 1801-11.
9. Baybis, M., et al., mTOR cascade activation distinguishes tubers from focal cortical  dysplasia. 
Ann Neurol, 2004. 56(4): p. 478-87.
10. Miyata, H., A.C. Chiang, and H.V. Vinters, Insulin  signaling pathways in cortical dysplasia and 
TSC-tubers: tissue microarray analysis. Annals of neurology, 2004. 56(4): p. 510-9.
11. Ljungberg, M.C., et al., Activation  of mammalian target of rapamycin in cytomegalic neurons of 
human cortical dysplasia. Ann Neurol, 2006. 60(4): p. 420-9.
12. Orlova, K.A. and P.B. Crino, The tuberous sclerosis  complex. Ann N Y Acad Sci, 2010. 1184:  p. 
87-105.
13. Talos,  D.M., et al., Cell-specific alterations of glutamate receptor expression in tuberous  sclerosis 
complex cortical tubers. Ann Neurol, 2008. 63(4): p. 454-65.
14. Talos,  D.M., et al., Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia. Annals 
of neurology, 2012. 71(4): p. 539-51.
15. Cloughesy, T.F., et al., Antitumor activity  of rapamycin in a Phase I trial for patients with recurrent 
PTEN-deficient glioblastoma. PLoS medicine, 2008. 5(1): p. e8.
16. Cloughesy, T., et al., A Phase II trial of everolimus  in patients with reccurent glioblastoma 
multiforme. Soc Neuro-oncol, 2011. Nov 18-20(Garden Grove,  CA).
17. Chang,  S.M., et al., Phase II study of CCI-779  in patients with recurrent  glioblastoma  multiforme. 
Investigational new drugs, 2005. 23(4): p. 357-61.
18. Pengel, L.H., L.Q. Liu, and P.J. Morris, Do wound complications  or lymphoceles  occur more often 
in solid organ transplant recipi[INVESTIGATOR_58825]? A systematic review of  randomized 
controlled trials. Transplant international : official journal of the European Society for  Organ 
Transplantation, 2011. 24(12): p. 1216-30.
19. Tedesco Silva, H., Jr., et al., Everolimus plus reduced-exposure CsA versus mycophenolic  acid 
plus standard-exposure CsA in renal-transplant recipi[INVESTIGATOR_840]. American journal of transplantation : 
official journal of the American Society of Transplantation and the American  Society of Transplant 
Surgeons, 2010. 10(6): p. 1401-13.
20. Eisen, H.J., et al., Everolimus for the prevention of allograft rejection and vasculopathy  in cardiac- 
transplant recipi[INVESTIGATOR_840]. The New England journal of medicine, 2003. 349(9): p. 847-58.
21. Lehmkuhl, H.B., et al., Everolimus with reduced cyclosporine versus MMF with  standard 
cyclosporine in de novo heart transplant recipi[INVESTIGATOR_840]. Transplantation, 2009. 88(1):  p. 115-22.
22. Zuckermann,  A., et al., Impact of de novo everolimus-based immunosuppression on incisional 
complications in heart transplantation. Transplantation, 2011. 92(5): p. 594-600.
23. Panaro, F., et al., Causes  of sirolimus discontinuation in 97 liver transplant recipi[INVESTIGATOR_840]. 
Transplantation proceedings, 2011. 43(4): p. 1128-31.
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 42
24. Knight,  R.J., et al., Risk factors for impaired wound healing in sirolimus-treated renal transplant 
recipi[INVESTIGATOR_840]. Clinical transplantation, 2007. 21(4): p. 460-5.
25. Flechner, S.M., et al., The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine,  
and steroids on wound healing  in 513 kidney-transplant recipi[INVESTIGATOR_840].  Transplantation,  2003. 76(12): 
p. 1729-34.
26. Krueger,  D.A.,  et al., Long  term safety  and efficacy  results from an extension  phase of an open-  
label, prospective, phase 1-2 trial of oral everolimus in patients with subependymal giant cell 
astrocytomas in Tuberous Sclerosis Complex. International Tuberous Sclerosis  Complex Alliance  
Research Conference, 2011. July 6-9, 2011(Washington DC).
27. Jozwiak, S., et al. Preliminary results from a double-blind, placebo-controlled,  phase 3 trial 
ofEverolimus in SEGAs associated  with Tuberous  Sclerosis Complex: EXIST-1 Study. in 
International Tuberous Sclerosis Complex Annual Conference. 2011. Washington DC.
28. Krueger DA, Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. 
Neurology. 2013 Feb 5;80(6):574-80. doi: 10.1212/WNL.0b013e3182815428.  Epub 2013 Jan 16.
29. Franz DN, Efficacy  and safety  of everolimus  for subependymal giant cell astrocytomas associated  
with tuberous sclerosis complex (EXIST-1): a multicentre, randomized, placebo-controlled phase 
3 trial. Lancet. 2013 Jan 12;381(9861):125-32. doi: 10.1016/S0140-6736(12)[ZIP_CODE]-9. Epub 2012 
Nov 14.
30. Cabrera Lopez, C., et al., Effects of rapamycin  on angiomyolipomas  in patients  with tuberous  
sclerosis. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia,  2011. 31(3): p. 292- 
8.
31 Hyman, M.H. and V.H. Whittemore, National Institutes of Health consensus conference: tuberous
32 Roach,  E.S.,  M.R. G omez,  and H. Northrup,  Tuberous sclerosis complex consensus 
conference: revised  clinical diagnostic  criteria. J Child Neurol, 1998. 13(12): p. 624-8.
32 Kwan, P., et al., Definition  of  drug resistant epi[INVESTIGATOR_002]:  consensus proposal by [CONTACT_58874]. Epi[INVESTIGATOR_8330],  2010. 51(6):  p. 1069-77.
33. Dorward IG, Titus JB, Limbrick DD, Johnston JM, Bertrand ME, Smyth MD 2011. Extratemporal, 
nonlesional epi[INVESTIGATOR_58826]: postsurgical  clinical and neurocognitive  outcomes. J Neurosurg 
Pediatr Feb;7(2):179-88. doi: 10.3171/2010.11.PEDS10265.
34. Johnston JM Jr, Mangano FT, Ojemann JG, Park TS, Trevathan E, Smyth MD 2006. 
Complications of invasive subdural electrode monitoring  at St. Louis Children's Hospi[INVESTIGATOR_307], 1994-  
2005. J Neurosurg. Nov;105([ADDRESS_63996]):343-7.
35. Lee JH, Hwang  YS, Shin JJ, Kim TH, Shin HS, Park SK 2008.  Surgical complications of epi[INVESTIGATOR_58827] : experience of [ADDRESS_63997];44(4):234-9. doi: 10.3340/jkns.2008.44.4.234. Epub [ADDRESS_63998] 30.
36. Musleh W, Yassari R, Hecox K, Kohrman M, Chico M, Frim D 2006.Low incidence of subdural 
grid-related complications in prolonged pediatric EEG  monitoring.Pediatr  Neurosurg.;42(5):284-7.
37. Onal C,  Otsubo  H, Araki T, Chitoku  S, Ochi A, Weiss S, Elliott I, Snead  OC 3rd, Rutka JT, Logan 
W 2003. Complications of invasive subdural grid monitoring in children with epi[INVESTIGATOR_002]. J 
Neurosurg. May;98(5):1017-26.
38. Simon SL,  Telfeian A, Duhaime  AC 2003.  Complications of invasive monitoring used in 
intractable pediatric epi[INVESTIGATOR_002]. Pediatr Neurosurg. Jan;38(1):47-52.
39. Siah, C.J. and C. Childs, A systematic review of the ASEPSIS scoring system used in non- 
cardiac-related surgery. Journal of wound care, 2012. 21(3): p. 124,  126-30.
40 Bruce,  J., et al. , The measurement and monitoring of surgical adverse events.  Health technology 
assessment, 2001. 5(22): p.  1-194
CONFIDENTIAL
This document and information is the propert y of the NYU School of Medicine and Langone Medical Center.  Do not  disclose or use 
except  as authorized in writing by [CONTACT_58831]:  09/20/18Page 43